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ABSTRACT 
EVALUATION OF THE EFFECT OF PULSED ELECTRO MAGNETIC 
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Background:  
Painful diabetic neuropathy, involving the lower limbs which is worse at night 
interferes with normal sleep and affects the quality of life. Pharmacotherapies used for 
diabetic neuropathy are not recommended for use in older adults and patients with heart 
disease. Pulsed Electro Magnetic Field (PEMF) therapy, has gained clinical interest in 
the present-day and is found to have analgesic, neuro stimulatory, neurotrophic actions. 
It is also observed that they modulate pain, influence nerve regeneration by 
depolarising, hyperpolarising or repolarising neurons. 
 
Aim and objectives: 
To determine whether low frequency PEMF therapy can reduce neuropathic pain 
and influence nerve regeneration and improve vascularity of foot in type-2 diabetes 
mellitus patients with painful sensory polyneuropathy.  
 
Methods and Methodology:  
The study included thirty patients of type-2 diabetes mellitus for more than ten 
years duration with painful neuropathy. They were subjected to PEMF therapy, 
delivering 1500 nTesla (10Hz frequency with square wave configuration) for 60 
minutes/ day for 21 days with a break after every 6 days. Before and after the PEMF 
therapy, pain assessment by Visual Analog Scale (VAS), assessment of Vibration 
Perception Threshold (VPT) of foot, nerve conduction study in superficial peroneal 
nerve, erythrocyte Super Oxide Dismutase (SOD) Levels and Tc-99 MDP three phase 
bone scan were performed.  
 
Results:  
 After the Pulsed Electro Magnetic Field therapy, there was a significant 
reduction (p<0.001) in Visual Analog Score and latency of Sensory Nerve Action 
Potential (SNAP) in Superficial Peroneal Nerve and a significant improvement 
(p<0.001) in the Vibration Perception Threshold, Nerve Conduction Velocity (NCV) 
and amplitude of SNAP in Superficial Peroneal Nerve. An increase in the peripheral 
blood flow indicated by significant increase in Integral 60-120 seconds, frequency of 
counts in blood pool, one hour delay, three hour delay and counts in bone scan along 
with reduction of Time to ½ Max. in Tc-99 MDP three phase bone scan were also 
observed. Erythrocyte Super Oxide Dismutase (SOD) levels has shown a significant 
increase (P<0.001) following PEMF therapy.  
 
Conclusion:  
 This study shows that PEMF improves peripheral circulation of foot in painful 
diabetic polyneuropathy, thereby reducing pain and influencing nerve regeneration. It 
also reduces oxidative stress by increasing Super Oxide Dismutase (SOD) levels. 
Hence, PEMF which addresses the pathogenesis of diabetic neuropathy rather than 
merely focusing on pain alleviation could be used as a potential treatment modality for 
treating painful diabetic neuropathy. It has the advantage of non-invasiveness, 
involves no medications and adverse effects.  
 
Key words: Pulsed Electro Magnetic Field (PEMF) therapy, Painful Diabetic 
Neuropathy, Nerve Conduction Study, Superficial Peroneal Nerve, Vibration 
Perception Threshold, Visual Analog Scale, erythrocyte Super Oxide Dismutase 
levels.  
[1] 
 
INTRODUCTION 
Diabetes mellitus, a common metabolic disorder, is associated with 
devastating complications that deteriorate the quality of life of affected patients 
all over the World. With little discrimination, it affects the rich and poor, young 
and old, industrialised and economically less developed countries in equal 
measures. Diabetes mellitus is a fast evolving epidemic throughout the World. 
As estimated by the International Diabetes Federation, the prevalence of diabetes 
mellitus all over the World has reached 8.3% in the year 2013, affecting 381 
million people (Fikri Zaki Muhammadi, 20141). It is also estimated that the 
prevalence may get doubled in 2030 (Wild S et al., 20042). 
The aetiology of Diabetes Mellitus is hyperglycaemia produced by insulin 
deficiency or insulin resistance. It generally presents with hyperglycaemia, 
polyuria, polydipsia and polyphagia. In long-term, this disease may damage 
nerves, kidneys, eyes, heart and blood vessels. 
 
Diabetes mellitus and diabetic foot problems in India:  
In India, more than 62 million people are suffering from this recently 
growing epidemic, corresponding to 7.1% of its total Adult population (IANS3). 
Diabetes mellitus contributes to approximately 1 million deaths in India every 
year (Vinik et al., 20004). Diabetes mellitus in long term, may lead to 
microvascular and macro vascular diseases which are increasing in prevalence 
along with the rising epidemic of diabetes mellitus.  
[2] 
 
A prevalence study by Ramachandran et al.5 has shown the prevalence 
of vascular complications in type 2 diabetes in Indian subjects as follows:   
Complication Prevalence in Indian subjects (%) 
Peripheral neuropathy 27.5 
Retinopathy 23.7 
Heart disease 11.4 
Nephropathy 5.5 
Peripheral Vascular disease 4.0 
Stroke  0.9 
 
It is clear from the above table that diabetic neuropathy, affecting 27.5% 
of diabetic population contributes to major disease burden. Peripheral 
neuropathy and associated recurring foot infections are very common in India 
(Viswanathan V et al.20006). It has been estimated that approximately 90,200 
million rupees every year is spent on diabetes foot care (Shobana et al., 20007). 
In diabetes patients, diabetic neuropathy is a frequent cause of morbidity and 
death (Vinik et al., 20004). Triad of causal factors for diabetic foot ulcers include 
neuropathy with/ without ischemia, deformity and trauma (Viswanathan V et 
al.20006). The peripheral neuropathy is the most important factor required to 
complete causal pathway to foot ulceration (Viswanathan V et al.20006, Singh N 
et al., 20058, Boulton AJ et al. 20049). With the upsurge in the prevalence of 
diabetes in epidemic proportion, incidence of diabetic ulcer, the most frequent 
[3] 
 
complication affecting lower limbs predominantly has also increased. The 
lifetime risk of development of a foot ulcer can go up to 25% in patients with 
diabetes. Around 30 per cent of diabetic persons more than 40 years of age suffer 
from diabetic foot ulcers (Singh N et al., 20058).  
 
Diabetic neuropathy:  
Diabetes is the most important cause of peripheral neuropathy, a disorder 
that affects the functioning of neurons (Boulton AJ et al. 20049). Around 50% of 
patients with diabetes suffer from neuropathy (Abbott CA et al., 201110). 
Diabetic neuropathy most commonly presents as Distal Symmetrical Poly 
Neuropathy (DSPN) accounting for 75% of diabetic neuropathies (Boulton AJ 
et al. 20049). Distal neuropathy is usually associated with progressive loss of 
both autonomic and somatic nerve fibres. Somatic fibres may be affected in a 
diffuse pattern leading to a sensory disorder or in a patchy fashion producing a 
motor disorder.  
 
Painful diabetic neuropathy:   
Pain is a useful sensation that indicates an impending or actual tissue 
damage which in turn leads to aversive or attentive actions for protecting the 
body from harm. The after effects of losing the ability to perceive pain is seen in 
diabetic neuropathy. Painful diabetic neuropathy is the most frequent cause of 
neuropathic pain contributing to 72% of neuropathy cases, of which around 64% 
had moderate to severe pain and around 50% of the patients reported pain-related 
[4] 
 
interference in their daily activities (IndINeP Study Group, 200811). Painful 
DSPN is nocturnal in nature and disturbs sleep (Zelman DC et al., 200612). It 
adversely affects the normal physical and mental functioning of individuals and 
hence the quality of life. The risk of painful diabetic neuropathy is common in 
type 2 diabetes patients is 85% more than that of type 1 diabetes (Abbott CA et 
al., 201110). Distressing tingling sensation, commonly known as dysesthesia is 
seen in almost half of the patients. Dysesthesia is usually described as “burning” 
or “shooting” or “electric-shock like” or “lancinating” or “knife-like” or 
“crawling” or “aching” sensations by the patients. Sometimes they may feel 
unusual sensations like feeling of “walking over pebbles or hot sand”. Existing 
few epidemiological studies reveal that the prevalence of painful DSPN is around 
10–26% (Abbott CA et al., 201110, Davies M et al., 200413, Davies M et al., 
200614). Nearly 12.5% of patients with diabetic neuropathy had never reported 
their symptoms to doctor and around 39% were not undergoing treatment for 
their pain (Daousi C et al., 200415) indicating that there is a substantial under 
diagnosis and under treatment of painful neuropathic symptoms.  
 
Present treatment for painful diabetic neuropathy:  
At present only three drugs are approved by FDA for treating painful 
diabetic neuropathy, namely Pregabalin, an anticonvulsant, Duloxetine, 
Serotonin Norepinephrine Reuptake Inhibitor (SNRI), and Tapentadol, an 
opioid/SNRI. These drugs are aimed at treating the pain rather than interfering 
with the pathogenic mechanisms responsible for painful diabetic neuropathy and 
[5] 
 
also known to cause disagreeable side effects. None of them are found to be more 
effective than the tricyclic antidepressants (Morello CM  et al., 199916) that were 
used in the past.  
Hence, treating painful diabetic neuropathy poses a challenge for both 
the treating physicians and the patients and there is a search for a potential 
treatment that could aim at pathogenesis rather than just the pain alleviation (Bril 
V et al. 201117).  
 
Pulsed Electro Magnetic Field (PEMF):  
Various research works focussing on the magnetic fields have proven 
their effect on various biological processes and its effectiveness in treating many 
clinical conditions (Shupak NM. 200318, Markov MS, 2007a19, Markov MS, 
2007b20). Application of PEMF of frequency ranging between 0.1 Hz to 20 Hz 
in animals and humans have shown to produce electrophysiological, 
neurochemical and biochemical changes (P.V.Sanker Narayan et al., 198521). 
Pulsed Electro Magnetic Field (PEMF) therapy, has gained clinical interest in 
the present-day and is found to have analgesic, neuro stimulatory, neurotrophic 
actions (Sisken BF et al., 198922, Sisken BF et al., 199323, Walker J et al., 199424, 
Macias MY et al., 200025, Mert T 2006a26). Literature has also advocated that 
PEMF has the ability of stimulating nerve growth, regeneration and recovering 
the function of nerves by in vitro studies and animal models (Walker JL et al., 
199424, Macias MY et al., 200025, Mert T 2006b27, Tasset I et al., 201228, Kim S 
et al., 200829). It is also observed that they modulate pain and influence nerve 
[6] 
 
regeneration by depolarising, hyperpolarising or repolarising neurons. Animal 
studies which were aimed at repair of damaged peripheral nerves have shown 
PEMF exposure helps in hastening the nerve regeneration (B.F.Sisken et al., 
199430). Many studies have proved that pulsed electromagnetic fields (PEMF) 
are capable of modifying the nerve function of diabetic neuropathy patients 
(Wrobel MP et al. 200831, Szymborska-Kajanek A et al. 201032). An element of 
pain reduction is also seen during magnetic field exposure which modulates 
both the exogenous and endogenous opioid systems (M.Kavaliers et al. 199133, 
E.Choleris et al. 200234, J.H. Jeong  et al. 200035). Nevertheless, the clinical 
application of PEMF is still under controversy (Bril V et al. 201117). Hence, more 
research is required for confirming the therapeutic effects of PEMF on Diabetic 
Peripheral Neuropathy.  
This study focusses on evaluating whether the low frequency and low 
intensity Pulsed Electro Magnetic Field (PEMF) therapy is effective in reducing 
neuropathic pain, is capable of influencing nerve regeneration and improving 
peripheral blood flow in type-2 diabetes mellitus patients with painful sensory 
polyneuropathy by assessing and comparing pain using Visual Analog Score 
(VAS), sensory nerve conduction in superficial peroneal nerve, Vibration 
Perception Threshold (VPT) of foot, erythrocyte Super Oxide Dismutase (SOD) 
levels, peripheral blood flow in foot using Tc-99 MDP 3 phase bone scan before 
and after administration of Pulsed Electro Magnetic Field Therapy.   
 
 
 

[7] 
 
REVIEW OF LITERATURE 
Diabetes mellitus:  
Diabetes mellitus clinically presents as hyperglycaemia caused either by 
chronic and/or relative insufficiency of insulin (Mathis D et al. 200136).  
 
Types of diabetes mellitus:  
Type 1 diabetes (Insulin-dependent diabetes mellitus):  
Type 1 diabetes is characterized by hyperglycaemia produced due to a 
complex disease process that mostly occurs after sudden onset of an auto 
immune process owing to genetic and environmental factors (Davies JL et al. 
199437). The pancreatic β cells of the islets of Langerhans are destroyed during 
this process resulting in insufficient insulin production (Keenan HA et al. 
201038). Administration of exogenous insulin remains the main stay of treatment.  
 
Type 2 diabetes (Non-Insulin Dependent Diabetes Mellitus):   
Most common cause of diabetes mellitus, contributing to 85% of total 
diabetes patients. Type 2 diabetes mellitus is characterised by peripheral insulin 
resistance associated with compensatory increase in insulin secretion by 
pancreatic islets ultimately resulting in reduced islet secretory function. 
Nevertheless, relative decrease in insulin secretion is the final event that is 
responsible for producing hyperglycaemia (Kahn SE et al., 199339). Reduced 
peripheral insulin sensitivity is predominantly noticed in tissues like skeletal 
muscle, liver and adipose tissue because of metabolism and glucose uptake 
occurring in these tissues.  
[8] 
 
Gestational diabetes:  
High blood glucose level in a pregnant women who is not previously 
diagnosed as diabetic. This type of diabetes poses great risk to both the mother 
and baby. Increased risk of developing type 2 diabetes in the later part of life 
may occur as a consequence of gestational diabetes.   
 
Complications of Diabetes Mellitus:  
Acute metabolic complications 
 Diabetic ketoacidosis 
 Non-ketotic hyperosmolar coma 
Long term vascular complications (Angiopathy) 
Microvascular (Damage 
to small blood vessels) 
Macro vascular (Damage to arteries) 
 Eyes: Retinopathy 
 Kidney: Nephropathy 
 Nerves: Neuropathy 
Heart: Affects Coronary blood vessels leading 
to myocardial infarction 
Brain: Affects Cerebral blood vessels causing 
stroke 
Chronic complications of diabetes:  Depression (Nouwen A et al. 201140, 
dementia (Cukierman T et al., 200541) and sexual dysfunction (Adeniyi AF et 
al., 201142, Thorve VS et al., 201143) 
 
Diabetic Peripheral Neuropathy (DPN):  
Diabetic Peripheral Neuropathy, a heterogeneous disorder, affects the 
nervous system presenting with diverse clinical manifestations. An 
internationally accepted simple definition for DPN is “the presence of symptoms 
and/or signs of peripheral nerve dysfunction in people with diabetes after the 
[9] 
 
exclusion of other causes”. Confirmation of diagnosis of DPN can be done by 
using quantitative electrophysiology and sensory testing. Most common type of 
diabetic neuropathy is Distal Symmetrical Poly Neuropathy.  
 
Types of Diabetic Peripheral Neuropathy: 
A. Distal Symmetrical Poly Neuropathy (DSPN) 
B. Radiculopathy 
C. Mono neuropathy or mononeuritis multiplex 
D. Autonomic neuropathy 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.Types of diabetic neuropathy. A. Distal Symmetrical Poly Neuropathy 
(DSPN), B. Radiculopathy, C. Mono neuropathy or mononeuritis multiplex, D. 
Autonomic neuropathy 
[10] 
 
Distal Symmetric Poly Neuropathy (DSPN):  
As defined by Tesfaye S et al.44, “DSPN is a symmetrical, length-
dependent sensorimotor polyneuropathy attributable to metabolic and micro 
vessel alterations as a result of chronic hyperglycaemia exposure and 
cardiovascular risk covariates”  
 
Clinical features of DSPN:  
DSPN is usually gradual or insidious in onset which is indicated by 
sensory symptoms. It involves the toes first followed by the feet and legs, 
spreading proximally. In severe cases, upper limb may also be involved in a 
similar fashion, beginning from the fingers. A proportion of patients also present 
with hyperalgesia, paresthesia and allodynia and around 40–50% of patients 
are found to suffer from pain due to diabetic neuropathy. Pain without any 
neuropathy on clinical examination is also seen in 10–20% of diabetes patients 
(Obrosova IG, 200945). With the progression of the disease, motor weakness of 
lower limb muscles may also occur. 
Some patients may even present with a foot ulcer, because the sensory 
loss is missed by the patient. Characteristic features of DSPN comprises of 
numbness, impaired pressure, vibration and joint position sensations. Presence 
of symptoms or signs of neuropathy along with nerve conduction abnormality is 
required for diagnosis of DSPN.  
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Diabetic neuropathy Pathogenesis:  
Hypotheses concerning the aetiology of diabetic neuropathy have elaborated the 
following factors:  
a. Metabolic insult to nerve fibres (Direct effect) (Greene DA et al. 
198846) 
b. Neurovascular insufficiency (Indirect effect) (Low PA, 198747, 
Cameron NE et al. 199448) 
c. Impaired neurotrophic assistance (Vinik AI et al., 199549)  
d. Damage produced by auto immune factors (Rabinowe SL et al. 
199050) 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Factors contributing to pathogenesis of diabetic neuropathy 
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Metabolic insult to nerve fibres:  
Majority of consequences of diabetes are mainly attributed to 
hyperglycaemia. Metabolic alterations in turn may lead to decrease in nerve 
blood flow and Nerve Conduction Velocity (Greene DA et al. 198846). Various 
metabolic alterations in diabetic neuropathy (Cameron NE et al. 199448) are:  
a. Increased polyol pathway flux  
b. Advanced glycosylation 
c. Elevated oxygen free radical formation 
d. Impaired metabolism of essential fatty acid (ω-6) and carnitine 
 
Polyol pathway:  
In normal individuals, reduction of glucose to sorbitol shields the cells 
against oxidative stress and derangement of NO action (Cameron NE et al. 
199448). Hyperglycaemia in diabetes leads to elevation in sorbitol levels which 
in turn gets converted into fructose, simultaneously converting NAD to NADH. 
Elevated sorbitol and fructose may lead to impaired nitric oxide, a vasodilator, 
leading to ischemia of nerve (Ando H et al., 200651). Fructose is ten times better 
substrate for glycosylation in comparison to glucose. Advanced glycosylation 
end products (AGEs) formation would be hastened by increased polyol pathway 
flux (Brownlee M, 199252). Furthermore, reduction in myo-inositol/ 
phosphoinositide metabolism has also been implicated (Greene DA et al. 
198846). Elevated sorbitol may result in an osmoregulatory compensation, 
leading to reduction in myo-inositol which may be explained by the compatible 
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osmolyte hypothesis ((Brownlee M, 199252). Further, this may result in impaired 
phosphoinositide turnover and reduced stimulation of protein kinase C by di-acyl 
glycerol. Decreased stimulation of Protein Kinase C is in turn attributed to 
decrease in Nerve Conduction Velocity via reduced Na+-K+-ATPase activity 
(Greene DA et al. 198846).  
 
 
 
 
 
 
 
 
 
 
Fig.3. Schematic diagram of polyol pathway in diabetic neuropathy 
 
Effects of Advanced Glycosylation: 
The process of glycation takes place in two phases: early reversible phase 
producing Amadori products and late irreversible phase producing Advanced 
Glycation End products (AGEs).  
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Glycosylation:   
Glycosylation is a type of enzymatic post translational modification. It is 
a site-specific and targeted process which involves the addition of glycans on to 
lipids, proteins and other organic molecules.  
 
N- Linked Glycosylation:  
N-linked glycosylation occurs within the endoplasmic reticulum (ER). 
Any defect in N-glycosylation may lead to accumulation of misfolded proteins 
intracellularly and improper trafficking of various intra cellular proteins. This 
phenomenon is called ER stress and is implicated as a pathological feature of 
diabetic complications (Kozutsumi Y et al., 198853). The unfolded protein 
response activate three major signalling cascades, namely, protein kinase RNA 
(PKR)-like ER kinase (PERK), inositol requiring protein-1 (IRE1), and 
transcription factor-6 (ATF6) pathway.  
ER stress protective pathways get overwhelmed in diabetes leading to 
initiation of pro apoptotic pathways (Kim R et al., 200654, Xu C et al., 200555).  
 
O-Linked Glycosylation:  
O-glycosylation, a late posttranslational process that occurs within the 
Golgi apparatus (Haltiwanger RS et al.199856), is a process involving addition 
(enzymatic) of galactosamine to serine or threonine residues followed by 
galactose or sialic acid. This is important for extracellular matrix proteins like 
[15] 
 
collagens and proteoglycans. In diabetic complications, there is excessive O-
GlcNAc modification of proteins (Brownlee M, 200157).  
 
Advanced Glycation:  
Advanced glycation is a non-enzymatic post translational modification of 
amino acids and free amino groups on proteins by covalent attachment of sugar 
moieties. This reaction, termed the “Maillard reaction” (Maillard  L, 191258), was 
first discovered hundred years ago. Some studies have shown that advanced 
glycation leads to modulation of insulin secretion (Coughlan MT  et al., 201159 
and signalling (Cassese A et al., 200860,  Reddy MA et al., 200661). 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Common post translational modifications in diabetes 
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The intracellular AGE damages the target cells through 3 pathways:  
1. N-Glycosylation: Modification of intracellular proteins and 
alteration of their function  
2. O-Glycosylation: Modification of extra cellular matrix components 
leading to abnormal interaction with other matrix constituents and cell 
protein receptors   
3. Advanced glycosylation: Modification of plasma proteins which 
bind to the AGE receptors present on various cells like endothelial, 
mesangial cells and macrophages leading to reactive oxygen species 
(ROS) generation (Fu MX et al., 199462). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Effect of Advanced Glycation End products  
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Free radicals:   
Atoms or molecules having one or more unpaired electrons are called free 
radicals. The presence of unpaired electron is responsible for their highly 
reactive and unstable nature (Halliwell, B, 199963). Reactive Oxygen Species 
(ROS) and Reactive Nitrogen Species (RNS) are chief free radicals that damage 
cells. Free radicals are continuously produced in aerobic cells, most commonly 
as ROS. Free radicals produced are then eliminated by antioxidants defence 
constituting enzymes like catalase, superoxide dismutase and glutathione 
peroxidise. 
 
Anti-oxidant mechanisms:  
Super Oxide Dismutase (SOD) is an enzyme that catalyses the conversion 
of superoxide anion into hydrogen peroxide and oxygen.  
O2− + O2− + 2H+ → H2O2 + O2 
Reactive Oxygen Species (ROS)64, 
65, 66, 67 
Reactive Nitrogen Species (RNS)  
Hydroxyl (OH) 
Superoxide (O2-) 
Hydro peroxyl (HRO2-) 
Peroxyl (RO2) 
Hydrochlorous acid (HOCl)  
Hydrogen peroxide (H2O2) 
Nitric oxide (NO) 
Nitrogen dioxide (NO2-) 
Peroxynitrite (ONOO-) 
Nitrous oxide (HNO2)  
Alkyl peroxynitrates (RONOO) 
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Activity of SOD was first discovered by McCord and Fridovich in 1969 
(Szaleczky, E et al., 199968). Consequently, they recognised that SOD was 
crucial in maintaining life in aerobic conditions (McCord et al., 197169). The 
hydrogen peroxide is converted in to water by the enzyme glutathione peroxidase 
(GPx).  
Microvascular disease in diabetes is found to alter the expression and 
functioning of antioxidant enzymes (Ceriello A et al., 200070, Hinerfeld D et al. 
2004 71, DeRubertis FR et al., 200772, Min D et al. 201273). 
 
Super Oxide Dismutase:  
SOD is a metalloprotein made up of a metal ion, either Copper-Zinc (Cu-
Zn), Manganese (Mn), Iron (Fe) or Nickel (Ni) (Fridovich, I, 199874) at its centre.  
Fe-SOD is usually seen in prokaryotes and plants. In humans, intra and 
extra cellular forms of Cu-Zn SOD and mitochondrial Mn SOD have been 
recognised.  
Intracellular Cu-Zn SOD is made up of two identical subunits (Tainer et 
al., 198275), each comprising of a Cu (II) and a Zn (II) ion. Catalytic activity of 
SOD is due to Cu (II) while stabilization of enzyme conformation is done by Zn 
(II) (Djordjević, B. V et al., 200076). Hydrogen peroxide inactivates cytosolic Cu-
Zn SOD by converting Cu (II) into Cu (II)–OH or the ionized form Cu (II)–O-.  
Extracellular SOD (ECSOD) is a tetrameric glycoprotein. Each subunit 
consists of a Cu and Zn atom. ECSOD exhibits high affinity for heparin sulphate, 
facilitating high concentration of ECSOD in specific regions like extracellular 
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space and on the cell surface. Expression of ECSOD is primarily increased by 
IFN γ and reduced by TNF α and TGF β. Decreased ECSOD expression in turn 
results in reduced mitochondrial GSH and increased oxidative stress (Lebovitz, 
R.M et al. 199677).  
Mitochondrial SOD (MnSOD) is found in the mitochondrial matrix. Two 
isoforms of MnSOD, dimeric MnSOD and tetrameric MnSOD have been 
identified. Each subunit of MnSOD consists of one Mn (III) ion. It is usually 
produced in a constitutive manner. Production of Mn (III) can be stimulated by 
IL-1, TNF or an endotoxin (Tang, L et al., 199478).  
 
Oxidative stress:  
Imbalance between production of reactive oxygen species (ROS) and 
antioxidant capacity may lead to oxidative stress. Oxidative stress can result 
either from increase in generation of ROS or any defect in functioning of 
antioxidant system.  
 
Effect of oxidative stress in diabetic neuropathy:  
Chronic hyperglycaemia is responsible for oxidative stress by enzymatic, 
non-enzymatic and mitochondrial pathways. 
Non-enzymatic pathway:  
Glucose reacts with proteins through a non-enzymatic process to reduce 
molecular oxygen to highly reactive superoxide radical, hydrogen peroxide, and 
hydroxyl radical.  
[20] 
 
Enzymatic pathway:  
The main source of reactive oxygen species in diabetes is autoxidation of 
excess glucose which is catalysed by free transition metal ions including iron or 
copper present in trace amounts. Another source of free radicals is AGEs (Fu 
MX et al., 199462). When endothelial cells were cultured in high glucose 
environment, they exhibited an abnormal GSH redox cycle, and reduction in 
NADPH and GSH levels and viability of endothelial cells were reduced when 
they were given a peroxide challenge (Kashiwagi A et al., 199479).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Role of oxidative stress in causing neurovascular dysfunction 
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Cofactor for aldose reductase, NADPH, is reduced due to elevated polyol 
pathway flux. This would in turn would impair the GSH redox cycle, resulting 
in significant increase in oxygen free radicals. This is followed by damage to the 
vascular endothelium and neutralization of Nitric Oxide, leading to reduction in 
vasa nervorum vasodilation. Superoxide radicals are removed enzymatically by 
Super oxide dismutase. During excessive production of superoxide radicals, as 
in diabetes, they react with nitric oxide to form peroxynitrite that causes neuronal 
damage (Djordjević, B. V et al., 200076). 
 
Mitochondrial pathway:  
Various studies have proven the mitochondrial functional abnormalities 
at regions of diabetic complications (Bugger H et al., 200980, Chowdhury SK et 
al., 201281, Coughlan MT et al., 200982, Roy Chowdhury SK et al., 201283, 
Shenouda SM  et al. 201184, Tewari S  et al. 201285, Zhong Q et al., 201286). In 
humans, more than 90% of oxygen metabolized during oxidative 
phosphorylation, a process in which glucose and other metabolites donate 
electrons for reduction of molecular oxygen resulting in ATP production, occurs 
in mitochondria. This is a highly regulated process. Under physiological 
conditions, only less than 1% of oxygen is partially reduced to form O2-. 
Remaining is converted to water by antioxidant enzymes. The major sites of 
electron leakage that produces superoxide within the mitochondria are NADH 
dehydrogenase (complex I) and interface between coenzyme Q (CoQ) and 
complex III (Turrens JF et al. 198087). In diabetes, superoxide (O2-) production 
[22] 
 
by dysfunctional mitochondria is being suggested as the principal initiating event 
in the process of development of diabetic complications (Nishikawa T et al., 
200088).  
 
Effect of essential fatty acids & L-carnitine derivatives:   
Hepatic A-6 desaturation of linoleic acid, main dietary source of ω6 
essential fatty acids, is reduced in diabetes. Subsequently, this results in reduced 
synthesis of vasoactive prostanoids like PGI2 by vasa nervosum of diabetic rats 
(Ward KK et al., 198989).  
 
Neurovascular insufficiency in diabetic neuropathy:  
Reduced sciatic nerve blood flow have been observed in experimentally 
induced diabetes by many researchers using a variety of tests like laser-Doppler 
flowmetry, [C14] butanol and [C14] iodoantipyrine accumulation test and 
hydrogen clearance microelectrode polarography (Cameron NE et al., 199448). 
Recent researches have established the presence of endoneurial hypoxia, 
resulting in reduced nerve conduction velocity (NCV) (Tuck RR et al., 198490, 
Maxfield EK et al., 199391, Cameron NE et al., 199492, Cameron NE et al., 
199493) and impaired sural nerve blood flow in neuropathy patients (Tesfaye S 
et al., 199494).  
Various functional defects found in the dermal microvasculature of 
diabetic subjects are decreased tissue pO2, reduced microvascular blood flow, 
increase in vascular resistance and altered characteristics of vascular 
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permeability. These result from impaired vasodilator responses to Substance P 
and calcitonin gene–related peptide (CGRP) and reaction to nociceptive 
stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Causal relationship between metabolic changes and peripheral nerve 
blood flow in diabetic neuropathy. AII- Angiotensin II, EFA- Essential Fatty 
Acid, ET- Endothelin-1, PGI2- Prostacyclin, VSM- Vascular Smooth Muscle 
[24] 
 
 
 
 
 
 
 
 
 
 
Fig.8. Neurovascular insufficiency in Diabetic neuropathy 
 
Impaired neurotrophic assistance:  
The neurons depend on the growth factors that are released from target 
tissue throughout life for their functioning, maintenance and survival. Recent 
studies have elucidated that sympathetic neurons and Dorsal Root Ganglion 
neurons are dependent on Nerve Growth Factor for maintenance (Calcutt, N. A. 
et al. 1990 95 and survival (Rich, K. M. et al., 198796). These group of neurons 
are most commonly affected in diabetic neuropathy. Nerve Growth Factor also 
appears to be an important regulator of adult DRG neurons synthesising 
Substance P (Lindsay,R. M. et al., 198997,  Schwartz, J. P. et al., 198298) which 
plays a major role in vasodilatation, gut motility, and nociception, affected in 
diabetic neuropathy. A dramatic reduction in Nerve Growth Factor levels are 
found in superior cervical ganglion, a NGF-dependent group of neurons in 
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Streptozotocin (STZ)-induced diabetic rats (Steinbacher-BC et al., 199899), that 
usually represents a syndrome mimicking type 2 diabetes. A study by Hellweg 
et al.,100 has shown a reduction in retrograde transport of Nerve Growth Factor 
in the sciatic nerve in STZ-induced diabetic rats.  
 
 
 
 
 
 
 
 
Fig.9. Balance between nerve destruction and neuroprotection in diabetic 
neuropathy   
 
Damage produced by auto immune factors:  
 Phospholipid autoantibodies (PLAs) constitute a family of closely related 
IgG, IgM, and IgA immunoglobulins that interact with negatively charged 
phospholipids (Triplett DA et al. 1988101, McNeil HP et al., 1991102). These 
PLAs are found to cross-react with neural phospholipids like sphingomyelin and 
cephalin, thereby damaging neural structures (Harris EN et al., 1985103, Harris 
EN et al., 1988104). Phospholipid Autoantibodies (PLA) are found in 88% of 
diabetic neuropathy patients (Aaron i. Vinik, md, phd et al., 1995105).  
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Painful Diabetic Neuropathy:  
Rollo (1798): First person to describe the diabetic neuropathic pain as “pain and 
paraesthesia found in the legs of a diabetic patient” (Boulton AJ et al., 20049) 
Pavy (1887): Described diabetic neuropathy pain as a “pain of a burning and 
unremitting nature”  
International Association for the Study of Pain has given a definition for 
peripheral neuropathic pain due to diabetes as “the pain arising as a direct 
consequence of abnormalities in the peripheral somatosensory system in people 
with diabetes.” (Treede RD et al., 2008106) 
 
Types of pain in diabetic neuropathy:  
Asbury and Fields have proposed a hypothesis that identifies specific painful 
symptoms of chronic painful diabetic peripheral neuropathy (Abbott CA et al., 
201110).  
3 types of pain have been described by the hypothesis. 
 Superficial pain  
 Deep pain  
 Muscle pain  
 
Superficial type of pain:  
Sensations like burning, allodynia and tingling arising from cutaneous or 
subcutaneous receptors are ascribed to nociceptive fibres that are damaged, 
sprouting and regenerating fibres that fire at increased rates.  
[27] 
 
 
 
 
 
 
Fig.10. Mechanism of superficial pain. Increased firing of damaged or 
abnormally excited nociceptive fibres, particularly sprouting regenerating fibres  
 
Deep pain:  
This pain arises from deeper anatomical structures. It is described as "pins 
and needles" or "electric-like" (Fields HL, 1987107). This pain results from:  
Spontaneous activity and 
increase in mechanosensitivity of 
damaged afferents in dorsal root 
ganglion 
 
Ectopic impulses produced by 
demyelinated patches of 
myelinated axons  
 
Modified gate control 
hypothesis: Loss of segmental 
inhibition of myelinated fibres 
(large) and unmyelinated pain 
fibres (small)   
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Increased firing of neurons due 
to physiological stimulation of 
nociceptive afferents that 
innervate the nerve sheaths (nervi 
nervorum)  
 
 
Muscular pain:  
Described as a “cramping pain”, “aching pain”, “muscle tenderness” or a 
"drawing sensation". This may be due to injury to motor nerves or due to a reflex 
loop "Livingston's vicious circle" (Livingston WK, 1943108). In this, an input, 
mostly nociceptive, activates the motor neuron in the spinal cord producing 
muscle spasm which in turn activates the nociceptors present in the muscle fibres 
and send feedback signal to the spinal cord and sustain the spasm.  
 
 
 
 
 
 
Fig.11. Livingston’s vicious circle. Involves a nociceptive input that activates 
the motor neuron within the spinal cord causing muscle spasms, in turn activating 
the muscle nociceptors and feeds back to the spinal cord to sustain the muscle 
spasm  
[29] 
 
Mechanism of neuropathic pain in diabetes:  
Despite several peripheral nerve studies, the genesis of diabetic neuropathic 
pain remains poorly understood. The precise pathophysiological mechanism that 
is responsible for neuropathic pain in diabetes could not be defined, although 
several mechanisms have been suggested (Tesfaye S et al., 2005109)  
 
Proposed mechanisms of pain generation in Painful diabetic neuropathy:  
 Inappropriate or exaggerated peripheral sensory neurons activity 
 Alteration in sensory processing within the spinal cord 
 Spontaneous activity in the central nervous system which is perceived as 
pain arising from the periphery  
 
 
 
 
 
 
 
 
 
 
Fig.12. Proposed mechanisms of pain generation in Painful diabetic neuropathy 
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The following mechanisms of genesis of pain in diabetic neuropathy was 
proposed by Tesfaye and Kempler (Tesfaye S et al., 2005109). 
Peripheral mechanisms 
 Changes in sodium channel distribution and expression 
 Changes in calcium channel distribution and expression 
Central mechanisms 
 Central sensitization 
 Changes in the balance of facilitation/ inhibition within descending 
pathways 
 
Peripheral mechanism:  
Alteration in sodium channel distribution and expression:  
Inherited pain disorders due to mutated sodium channels (Yang Y et al., 
2004110, Cox JJ et al., 2006111) and polymorphisms of sodium channel have 
impact on the level of pain in patients, indicating that differences in sodium 
channel distribution might explain variability in pain seen in patients with DSPN 
(Reimann F  et al., 2010112). In damaged peripheral nerves, the normal 
distribution of sodium channels along a nerve is altered due to neuroma. There 
occurs an accumulation of sodium channels at or around the site of injury 
resulting in “ectopic” activity. The potassium channels acts as molecular brakes 
of excitable cells, thereby modulating neuronal hyper excitability. 
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Alteration in voltage-gated Ca2+ channel distribution and expression:  
Voltage gated calcium channels serve to release transmitters, glutamate 
and substance P in pain fibres. Peripheral nerve injury leads to upregulation of 
α2δ subunits of voltage gated calcium channels, resulting in increased release 
of the neuro transmitters at the spinal cord (Bauer CS et al., 2009113). 
 
Central mechanisms:  
Studies concerned with changes in central nervous system following 
peripheral nerve injury have demonstrated increase in thalamic vascularity 
(Selvarajah D et al., 2011114), abnormal firing of thalamic neurons (Lenz FA et 
al., 1987115) and variations in concentration of metabolites in the thalamus 
(Pattany PM et al., 2002116). Aδ and C fibres that mediate pain terminate in the 
superficial laminae of the dorsal horn. These fibres finally project to limbic 
cortex, thalamus, nucleus tractus solitarius, periaqueductal gray, lateral 
parabrachial nucleus and the medullary reticular formation. Following 
neuropathy, the threshold of some of the neurons get reduced and results in hyper 
excitability of neurons. This in turn leads to increased response to all subsequent 
inputs, innocuous and noxious, explained by expanded receptive fields and 
augmented output to higher levels of the brain, termed central sensitization.  
Diabetic neuropathic pain is worse at night due to nocturnal changes in these 
central pain processing areas.  
 
 
[32] 
 
 
 
 
 
 
 
 
 
 
 
Fig.13. Pathways of pain. NA- Nor adrenaline, NMDA- N-Methyl D-Aspartate, 
PAG- Peri Aqueductal gray, LTP- Long Term Potentiation, RVM- Rostro 
Ventral Medulla  
 
Present treatment available for diabetic neuropathy:  
The effectiveness of using tricyclic antidepressants in DSPN has been 
documented by various randomized controlled trials (Max MB et al., 1992117, 
Finnerup NB et al., 2005118, Tesfaye S, 2009119).  
 
Tricyclic anti-depressants (TCA):  
Small doses (10 mg) of either amitriptyline or imipramine are usually 
prescribed at night. Use of TCA treatment of diabetic neuropathy has become 
limited because of the undesirable anticholinergic side effects like dryness of 
[33] 
 
mouth, sedation, sweating and dizziness. Recent studies have proved that they 
also increase the risk of sudden cardiac death in diabetic patients with 
cardiovascular disease (Ray WA et al., 2004)120.  
 
Serotonin Noradrenalin Re-uptake Inhibitors (SNRI):  
Duloxetine, a Serotonin Noradrenalin Re-uptake Inhibitors (SNRI) act by 
increasing the synaptic availability of 5-hydroxytryptamine (5-HT) and 
noradrenaline in the descending pathways that inhibit pain impulses. Duloxetine 
at doses of 60 to 120 mg/day has been proved effective in treatment of painful 
diabetic neuropathy Goldstein DJ et al., 2005121, Raskin J et al., 2005122, 
Wernicke JF et al., 2006123). The most frequent side effects of duloxetine, usually 
mild and transient, are nausea, dry mouth, somnolence, dizziness, constipation, 
and reduced appetite.  
 
 
 
 
 
 
 
 
 
Fig.14. Pharmacological treatment of diabetic neuropathy 
[34] 
 
Gabapentin and pregabalin:  
Gabapentin and pregabalin act by binding to the α-2-δ subunit of calcium 
channel and reducing calcium flux and thereby limiting the neurotransmitter 
release from the hyper excited neurons. 
 
PRINCIPLES OF SENSORY NERVE CONDUCTION 
Nerve Action Potential:   
Application of electrical stimulus to a nerve fibre, either sensory or motor, 
leads to opening of voltage-gated Na+ channels in the membrane of nerve fibre 
and influx of sodium which in turn produces a local depolarization of the 
membrane. On attaining the threshold for depolarization, a self-sustaining action 
potential is produced at that site and it propagates along the nerve fibre by 
depolarizing the membrane in a sequence along both the directions from the 
point of stimulation. 
 
Sensory Nerve Action Potential (SNAP):  
The action potential generates an electrical field which is measured at a 
small distance from the nerve fibre. In a nerve trunk, when many nerve fibre 
action potentials propagate simultaneously, their electrical fields in the 
surrounding region get summated and this region is termed as volume conductor. 
SNAP represents the sum total of action potentials recorded from all nerve fibres 
present in the volume conductor. Sensory nerve conduction studies involve 
stimulation of the nerve and direct recording of the sensory nerve action potential 
[35] 
 
(SNAP) by surface electrodes placed over the nerve. The magnitude of the 
response falls as a function of the square of distance between the site of stimulus 
application and the recording electrode.  
 
Recording of SNAP:  
Sensory nerve conduction may be performed antidromically or 
orthodromically. The stimulation at distal portion of the nerve and recording the 
sensory nerve action potential proximally along the nerve is called orthodromic 
conduction. The stimulation at proximal part of the nerve and recording the 
sensory nerve action potential at the distal part of the nerve is known as 
antidromic conduction. In orthodromic conduction, the impulses travel in the 
same direction as that of sensory impulses, whereas in antidromic condition, the 
impulses travel in the opposite direction as that of sensory impulses (Binnie CD 
et al., 2004124). Antidromic technique is preferred over orthodromic technique.  
 
Patient Position: Comfortable, resting posture.  
Electrode Placement:  
Active (recording) electrode and reference electrodes: Placed over the 
segment of nerve which is being studied and active electrode is placed distal to 
reference electrode 
Ground electrode: Placed over a bony prominence amid stimulating and active 
(recording) electrodes 
[36] 
 
Electrostimulation: Stimulation is given percutaneously using surface 
electrodes along the course of the nerve segment under study.  
Cathode (negative pole) of the stimulating electrode must be placed towards the 
active (recording) electrode. 
 
Sensory nerve action potential (SNAP) 
SNAP is a tri phasic potential. It has an initial and terminal positivity separated 
by a negative deflection. The negative deflection indicates the time of impulse 
arrival beneath the active electrode.  
 
 
 
 
 
 
Fig.15. Sensory Nerve Action Potential- Triphasic potential with initial and 
terminal positive peaks (a & c) and middle negative peak (b)  
 
Parameters that are measured in sensory nerve conduction study:  
1. Amplitude  
2. Latency  
3. Nerve conduction velocity  
4. Duration  
[37] 
 
Amplitude:  
The amplitude of a sensory response in microvolts is “measured from the 
peak of the negative phase to the peak of the positive phase of the sensory 
response”. It is associated with the number of axons that are viable. The SNAP 
amplitude is the algebraic sum of the electrical activity recorded at the two 
electrodes. If active and reference electrodes are placed close to each other, both 
the electrodes become active and this may distort the waveform and decrease the 
amplitude of action potential (Willbourn AJ  1994125). Hence, distance between 
active and reference electrode should be at least 3 cm, in order to clear the 
potential at active electrode before the activity begins at the reference electrode. 
SNAP amplitude usually varies from 5 to 200 µV.  
 
 
 
 
 
 
Fig.16. Measurement of SNAP amplitude. a- base to peak amplitude and b-
peak to peak amplitude. 
 
Latency:  
Time lapsed from the stimulus application to the onset of response is 
known as latency. Latency is related to the propagation of impulse along the 
[38] 
 
nerve. Latency for sensory nerve conduction is calculated from the onset of 
stimulus to peak of the response and is expressed in millivolts. The onset latency 
of SNAP is representative of the nerve conduction time and hence one site of 
stimulation is sufficient for sensory nerve conduction studies.  
Conduction latency time (milliseconds) for a sensory response is 
“measured from the stimulus artifact to the peak of the negative phase of the 
sensory response”.  
 
 
 
 
 
 
Fig.17. Measurement of latency of SNAP. a- onset latency and b-peak latency  
 
3. Duration:  
Duration is measured “from the initial positive peak to the junction between 
baseline and the descending wave”. The duration (milliseconds) of a motor or 
sensory response is measured “from the initial deflection of the negative phase 
of the response from the iso-electric baseline to the return of the positive phase 
of the response to the iso-electric baseline”.  
 
 
 
[39] 
 
 
 
 
 
 
 
 
 
Fig.18. Measurement of duration of SNAP. a - onset to intersection between 
the descending phase and base line, b – onset to negative peak, c – onset to 
positive peak and d – onset to return to base line.  
 
4. Sensory Nerve Conduction Velocity (SNCV):  
SNCV is the ratio of distance (in millimetre) between the centre of 
stimulating electrode and recording electrode to the latency (in milliseconds).  
SNCV (m/s) = Distance between stimulating and recording electrode 
      Latency  
 
 
 
 
 
      
Fig.19. Normal and abnormal Sensory Nerve Action Potential 
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Clinical applications of nerve conduction study:   
Nerve conduction study helps in detecting the nerve damage and 
determining the pattern of nerve damage. Nerve damage may be either axonal 
degeneration or demyelination. Usually, a mixed pattern with both axonal loss 
and demyelination occurs. Axonal loss may lead to slowing of conduction due 
to secondary demyelination and severe demyelination may lead to secondary 
axonal loss.  
 
Axonal degeneration  
Axonal loss usually follows neuronal cell death or injury to distal 
segment. This leads to interruption of impulse transmission at the most distal part 
of the axon, termed as a ‘dying back phenomenon’ (Cavanagh JB., 1964126). 
Pathological changes seen in axonal loss are axolemmal and myelin sheath 
disruption, loss of cytoskeletal elements without affecting the Schwann cells 
(William W. Campbell., 1999127). Electrophysiological changes seen in pure 
axonal loss are decrease in the amplitude of action potential with preservation of 
conduction velocity as the axons which survive conduct at normal velocity 
(Binnie CD et al., 2004124).  
 
Demyelination:   
Demyelination primarily affects either the myelin sheath or Schwann cell 
and the axon is intact. Demyelination may be para nodal or Segmental 
demyelination affecting the whole segment of myelin sheath. 
[41] 
 
Electrophysiological changes seen in demyelination are conduction block in 
particular node with normal distal nerve conduction in the case of para nodal 
demyelination and  decrease in conduction velocity with normal amplitude of 
action potentials in segmental demyelination (Bostock H., 1993128). 
 
Nerve conduction study in DPN:  
Currently, Nerve conduction studies (NCS) remain the most sensitive and 
specific method for detection of Diabetic Peripheral Neuropathy (Perkins BA, 
2001129). Nerve conduction studies provide a quantitative confirmation of 
Diabetic Peripheral Neuropathy (Boulton AJ et al., 2005130). Widespread use of 
Nerve Conduction Study has helped in early diagnosis and superior outcomes 
(Perkins BA et al., 2003131). Sensory nerve conduction is most commonly used 
for finding the response to a treatment (Sisken BF et al., 199323). A study by Y.L. 
Lo et al., 132 has compared the superficial peroneal and sural NCS for detecting 
peripheral neuropathy and has found superior results with Superficial Peroneal 
Nerve.  
 
History of using magnets in treating diseases:  
Since 15th century, various biological effects of low-level magnetic fields 
are being studied. Swiss physician, Paracelsus, during early 16th century, 
introduced the novel idea of using magnets in treating diseases like epilepsy, 
diarrhoea and haemorrhage (Mourino, M., 1991133). Later during the middle of 
18th century, magnetic therapy became more popular, when an Austrian doctor, 
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Franz Mesmer, started his magnetic healing salon in Paris. Dr.Thatcher had 
remarked that "magnetism properly applied will cure every curable disease no 
matter what the cause is." (Thatcher, C. 1886134). 
 
Electromagnetism:  
Electromagnetism was first discovered by the ‘English physicist Michael 
Faraday’, during 18th century. He found that ‘on allowing an electric current to 
flow through a coil, it generated a magnetic field and in other hand, a varying 
magnetic field produced an electric voltage’. The magnetic field must be 
changing in order to produce an electric effect. Biological effects of Pulsed 
Electromagnetic Fields are assumed to be because of electrical rather than 
magnetic forces. 
 
Voltage generated by magnetism in a tissue is given by the equation: 
V = n x a x dB/dt 
‘V’ = ‘Voltage’ 
‘n’ = ‘Number of turns in the electromagnetic coil’ 
‘a’ = ‘Area of the loop’ 
‘dB/dt’ = ‘Rate of change of magnetic field with respect to time’ 
‘B denotes the strength of the magnetic field (in Teslas)’ 
From this equation, it can be deduced that a static magnetic field does not 
produce any electrical voltage, as the ‘dB/dt component’ of the equation 
becomes zero.  
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The magnetic field generated by the movement of electrons are a field of 
virtual photons that initiate force lines. This magnetic field make the particles 
with an electric charge such as ions, to move. This force is known as a Lorentz 
force. 
 
Bio electromagnetics:  
Bio electromagnetics deals with the study of interaction between the 
biological system and non-ionising electromagnetic fields. Any modality that 
uses electricity and produces both an electric and a magnetic field is called 
electromagnetic modality. Movement of electrons (Flow of electricity) and the 
resultant ‘coupled magnetic field’ that is produced by the movement of electrons 
altogether is named as Electromagnetic radiation. Specific biological responses 
are generated by specific types of ELF Electromagnetic Fields based on certain 
parameters (Magnitude, frequency, wave form) (B.Rubik, 1997135). A subsection 
of Extremely Low Frequency Electromagnetic Fields, called Pulsed Electro 
Magnetic Field (PEMF) includes frequencies at the lower end of the 
electromagnetic spectrum, say from 6 Hz to 500 Hz (C.A.Bassett, 1989136). 
Voltages ranging from 10 µV and 1 mV/cm produced with a frequency of < 1 
Hz to 100 Hz result in an electric field, whether arising endogenously or 
produced exogenously by inductive coupling, appropriately configured, pulsing 
magnetic fields, have the potential to affect the functioning of various cells 
(McLeod KJ  et al., 1990137).   
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Mechanism of action of PEMF:  
The main effect of PEMF is due to induced electric field component rather 
than magnetic field component (C.A.Bassett, 1989136, Bassett CAL, 1993138, 
Pilla AA et al., 1992139). Electromagnetic modalities generate an electrical field 
using direct current running between the electrodes, leading to electrons mobility 
which is expected to influence the excitable cells by making ions within the 
excitable cells to move towards the respective electrodes and thereby, affecting 
physiology of the cell. Negative ions like chlorine (Cl-) are attracted towards the 
positive pole (anode), and positive ions like Sodium (Na+) move towards the 
negative pole (cathode). The levels of stimulation achieved with stimulating 
excitable cells may be sub sensory, sensory, motor and noxious (Panagopoulos 
DJ et al., 2002140). 
If we use a simple direct current wherein the electrons are flowing only 
in a single direction, there would be accumulation of like-charge ions in one 
region. This would increase the concentrations of hydrochloric acid and sodium 
hydroxide, thereby affecting the local pH which may in turn lead to pain and 
cellular damage. When we use a current which is alternating and bi-directional 
in nature, the disproportionate accumulation of ions near an electrode can be 
prevented.  
Panagopoulos et al. put forward a hypothesis stating that ‘externally 
applied electromagnetic field’ makes the ions to vibrate (Ganesan K et al., 
2009141). This vibration, upon reaching a ‘critical point’, generates a ‘false 
signal’ to the voltage gated channels present in the membranes of eukaryotic 
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cells. This false signal, forces the voltage gated channel to either ‘open or close’ 
affecting the cellular physiology. Panagopoulos et al. has also described the 
similarity in effects of the oscillating electric and magnetic fields on the free ions 
and subsequently the ‘voltage gated ion channels’. The theory put forward by 
Panagopoulos et al. states that, the amplitude of the “ion’s forced vibration” is 
inversely related to the frequency, and hence electromagnetic fields in the lower 
frequency ranges have the likely to be more bioactive.  
 
PEMF acts through two mechanisms:  
a. By stabilising cytosolic calcium (Ca2+) 
b. Restoring equilibrium between free radicals and antioxidants  
 
Stabilisation of cytosolic calcium ions:  
Electro Magnetic Field signals act as a first messenger that modulates 
Calmodulin (CaM) dependent pathways (A.A. Pilla, 2007142) which is normally 
activated by increased cytoplasmic free calcium ions (Ca2+) concentration 
following insult, injury and stress (M.J. Berridge et al., 2003143). Most important 
pathway that rapidly responds to physical, chemical insults in various tissues is 
the CaM-dependent nitric oxide (NO) signalling pathway. Nitric oxide, a 
gaseous free radical, is capable of diffusing locally across membranes and 
organelles and exerts effect on molecular targets located within 200 μm (N.M. 
Tsoukias, 2008144). Nitric Oxide activates soluble guanylyl cyclase (sGC). 
Guanylyl cyclase in turn catalyses synthesis of cyclic guanosine monophosphate 
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(cGMP) (Cho HJ et al., 1009145). The CaM/NO/cGMP signalling pathway is 
capable of modulating peripheral and cardiac blood flow during physiological 
states and inflammation (D.S. Bredt, et al., 1990146), regulating the interleukin-
1beta (IL-1β) production (K. Ren et al., 2009147) and growth factors like vascular 
endothelial growth factor (VEGF) production and fibroblast growth factor (FGF-
2) (S. Werner  et al., 2003148).  
 
 
 
 
 
 
 
 
 
 
 
Fig.20. Mechanism of action of PEMF 
Following an injury, e.g., a bone fracture or a surgical incision, repair 
commences with an inflammatory stage during which the pro-inflammatory 
cytokine IL-1β is rapidly released.  This signalling pathway can also activate 
adenylyl cyclase (AC) that catalyses the formation of cyclic adenosine 
monophosphate (cAMP).  
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Recently, it has been proposed that CaM/nNOS/NO signalling may 
regulate the neuronal cell differentiation (Soo-Jin Oh1 et al., 2010149).  Besides 
increasing cell metabolism, PEMF has the ability to ameliorate inflammatory 
effects by reducing inflammatory cytokines. 
 
Restoring equilibrium between free radicals and antioxidants:  
Almost all the chronic diseases result from an imbalance in homeostasis 
between the free radicals and antioxidants. Together, the free radicals and 
antioxidants, are essential for processes occurring within the cell, for instance, 
cellular respiration and immunity. Any discrepancy can result in death of cell 
and tissue, damage to DNA and degradation of protein and fat. As suggested by 
Gordon150, PEMF also has another essential effect, the ability of the magnetic 
fields to restore “equilibrium in ROS (free radicals)/antioxidants”.  
Gordon elaborates that both reactive oxygen species (ROS) free radicals 
like superoxide anion (O2-) and hydroxyl anion (OH-) are paramagnetic in nature 
and they will be affected by a magnetic field (analogous to the effect on ions: 
K+, Na+, Cl-, Ca2+). These para magnetic species are attracted by the 
electromagnetic field and undergo dipole alignment in a magnetic field 
(Zumdahl S., 1992151). It is assumed to increase the homeostasis between ROS 
and antioxidants.  
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Effect of PEMF on various cells:  
Study  PEMF 
parameters  
Inference from the study  
Richards TL et 
al152 
75 Hz, 2.3 mT  Increased number of chondrocytes 
Mattei MD et 
al.153 
15 Hz, 0.1 mT Increased proliferation of osteoblasts 
Gomez Ochoa et 
al.154 
75 Hz, 0.2mT 
– 3.5mT 
Saturation of adenosine receptors causing 
decreased inflammatory cytokine cascade 
Farndale R et 
al.155 
50 Hz, 2.25 
mT 
Significant increase in the Pro 
inflammatory cytokine levels, IL-1β and 
TNF-α 
Delle Monache 
S et al.156 
15 Hz, 4.8 ms 
pulse 
Reduction in cAMP levels leads to 
increased collagen cell proliferation  
Pipitone N et 
al.157 
50 Hz, 1mT Increased endothelial cells proliferation 
resulting in  angiogenesis 
Fini M et al.158 6 weeks of 
once-daily 
stimulation  
PEMF enhances osteo integration of 
hydroxyapatite into cancellous bone 
 
Studies concerned with effect of PEMF on various clinical conditions:  
1. Musculoskeletal disorders:   
a. Non-union of bone fractures   
 Bassett et al.159 reported radiographic evidence of osteogenesis in 25 of 
29 surgically resistant non-union patients after 75 Hz PEMF for one 
month  
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 Heckman et al.160 demonstrated enhancement of bone healing after 3 
months of PEMF therapy in 149 non-union patients with 85% success 
rate  
 Frykman et al.161 showed healing of non-union of scaphoid fractures in 
44 patients with 80% success rate using PEMF as an alternative to long 
arm cast  
b. Rheumatoid arthritis:  Ganguly et al.162 evaluated the effectiveness of 
PEMF in 35 patients with rheumatoid arthritis. Results showed an earlier 
improvement in pain, tenderness, swelling, physical disability and joint 
spasm and deformity in seronegative rheumatoid arthritis patients compared 
to seropositive individuals.   
c. Osteoarthritis:  
 Piptone et al.163 used 7.8 Hz (morning) and 3 Hz (evening) of PEMF in 
patients with osteoarthritis knee. This study reported significant 
improvements in pain, physical disability and stiffness scores after 
PEMF therapy compared to their baseline scores 
 Jacobson et al.164 demonstrated reduction of pain in patients with 
osteoarthritis knee using low amplitude and extremely low frequency 
magnetic field therapy. 
2. Soft tissue regeneration   
a. Venous leg ulcers 
 Ieran et al.165 did a double blind study for the treatment of patients 
with venous leg ulcers with 75 Hz PEMF for 90 days. They showed a 
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significant success rate of 66% in patients exposed to PEMF and 
follow up of these patients for 1 year post PEMF therapy revealed a 
decrease in recurrence of ulcers. 
 Stiller et al.166 did a multicentre, prospective, randomised double-blind 
study for treatment of recalcitrant venous ulcers using PEMF for 12 
weeks. The results showed a significant (47.7%) decrease in wound 
depth and only 15% increase in healthy granulation tissue. 
3. Neurological disorders  
a. Median-ulnar nerve injury: Wilson et al.167 assessed the median-ulnar 
nerve regeneration in the forelimb of 132 rats administering PEMF for 2 
months. The results indicated rapid regeneration of the median-ulnar nerve 
b. Peroneal nerve injury: Raji et al.168 used male Lewis rats to assess the 
effect of PEMF on peroneal nerve injury. The results showed a significant 
increase in number of nerve fibres indicating nerve regeneration and 
improvement in toe spreading reflex. 
c. Sciatic nerve injury: Kanje et al.169 demonstrated a significant sciatic 
nerve regeneration following crush injury to male and female rats with 
PEMF of 2 Hz exposed for 1 hour daily.  
d. Multiple sclerosis: Richards et al.170 evaluated the effect of PEMF (4-13 
Hz, 10-20 hours/ day for 2 months) in patients with multiple sclerosis. The 
results revealed improvement in performance scales and increase in alpha 
EEG during language tasks.  
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e. Tinnitus: Roland et al.171 performed a randomized double-blind study for 
the treatment of tinnitus. The results showed a significant reduction of 
sensation level (45%) and improvement in symptoms. 
f. Cerebral ischemia: Grant et al.172 demonstrated a significant reduction 
(65%) in cortical oedema (neocortex and neostriatum) in a rabbit model 
with focal cerebral ischaemia.    
4. Coronary disorders  
 DiCarlo et al.173 did a study on cardiac anoxia damage in chick embryo 
using 60 Hz of PEMF therapy. The results showed a significant (68.7%) 
increase in survival rates following PEMF therapy. 
 Albertini et al.174 showed a reduction in necrotic region of myocardial 
infarct following 60 Hz PEMF therapy   
 
Studies concerned with effect of PEMF on diabetic neuropathy:  
Weintraub et al.175 studied the effectiveness of repeated and cumulative 
effect of PEMF in reduction of neuropathic pain, sleep disturbance and nerve 
regeneration in 225 diabetic neuropathy patients. The study subjects were 
exposed to PEMF or sham for 2 hours/ day for 3 months. The study concluded 
that 31 mT magnetic field exposure did not reduce neuropathic pain however, 
Epidermal Nerve Fibre Density (ENFD) was found to increase (p =0.04) and 
itching sensation was reduced (p= 0.48).  
Vinay Graak et al.176 compared the effect of PEMF of frequencies 600 
Hz and 800 Hz in diabetic neuropathy patients. It was a randomized double 
[52] 
 
blinded controlled trial that included 30 diabetic neuropathy patients, of which 
10 were exposed to 600 Hz PEMF, 10 were exposed to 800 Hz PEMF and the 
remaining 10 served as a control. Significant reduction in pain and improvement 
in distal latency and Nerve Conduction velocity (NCV) (P<0.05) was observed 
in groups that were given PEMF in comparison to the control group.  
Tao Leil et al.177 evaluated the therapeutic potential of PEMF in relieving 
symptoms of diabetic peripheral neuropathy in experimental streptozotocin 
(STZ)-induced diabetic adult male Sprague–Dawley rats. The exposure group 
received 8 hours of PEMF for 7 weeks. The study revealed that PEMF 
stimulation mitigated the abnormalities in STZ-treated rats with DPN. There was 
an increase in hind paw withdrawal threshold, reduced demyelination and axon 
enlargement, less immunostaining of VEGF in sciatic nerve in exposure group 
in comparison with non-exposure group.  
Ismail Gunay et al.178 evaluated the effect of PEMF on regenerating 
peripheral nerves conduction characteristics of injured sciatic nerves in rats by 
using sucrose-gap recording technique. The study demonstrated the absence of 
abnormal hyperpolarizing after potentials and delayed depolarisation (found in 
injured nerves) following PEMF application. PEMF treatment for 38 days after 
injury produced significant differences in the conduction of Compound Action 
Potentials (p<0.05).  
Musaev et al.179 compared the effectiveness of 10 Hz and 100 Hz PEMF 
for Diabetic neuropathy and reported that 10 Hz is more effective in comparison 
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to 100 Hz for treating sensory deficits in diabetic neuropathy. The drawback of 
this study is that it does not include any control group.    
Wrobel et al.180 assessed influence of low frequency magnetic field on 
intensity of pain, sleep, quality of life and glycaemic control in painful diabetic 
polyneuropathy patients. This was a randomized, double-blinded placebo-
controlled study that included 61 patients. The study group with 32 patients were 
exposed to low frequency magnetic fields for 20 min a day, five days a week for 
3 weeks. The pain reduction did not differ significantly between the study and 
the control group.  
Webb et al.181 administered PEMF of 12 Hz frequency for 30 minutes and 
in foot of diabetes mellitus patients and had found an increase in peripheral blood 
flow and skin microcirculation.   
Cieslar, G et al. 182 employed sinusoidal magnetic fields for 12 minutes a 
day to treat diabetic neuropathy. The study demonstrated reduction in pain and 
paraesthesia and improvement in vibration sensation and muscular strength in 
85% of patients in comparison to controls.  
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AIM AND OBJECTIVES 
Aim: 
To determine whether low frequency Pulsed Electro Magnetic Field 
therapy (PEMF) can reduce neuropathic pain, influence nerve regeneration and 
improve vascularity of foot in type-2 Diabetes mellitus patients with painful 
sensory polyneuropathy  
 
Objectives:  
1. To  administer Pulsed Electro Magnetic Field therapy to Type-2 diabetes 
mellitus patients with painful diabetic sensory neuropathy 
2. To do nerve conduction study in superficial peroneal nerve and to assess 
and compare the distal latency, amplitude and nerve conduction velocity 
before and after Pulsed Electro Magnetic Field therapy   
3. To assess and compare the neuropathic pain before and after the Pulsed 
Electro Magnetic Field therapy using Visual Analog Scale 
4. To assess and compare the vibration Perception Threshold using 
Biothesiometer before and after Pulsed Electro Magnetic Field therapy 
5. To assess and compare the vascularity in foot before and after Pulsed 
Electro Magnetic Field therapy using Tc-99 MDP 3 phase bone scan  
6. To assess and compare the erythrocyte Super Oxide Dismutase levels 
before and after the Pulsed Electro Magnetic Field therapy  
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MATERIALS AND METHODS 
The study was conducted during the period of June 2014 to May 2015 at 
the Institute of Physiology and Experimental Medicine, Madras Medical College 
and Institute of Diabetology, Rajiv Gandhi Government General Hospital after 
obtaining approval from Institutional Ethics Committee (IEC), Madras Medical 
College, Chennai-3. 
 
Selection of subjects: 
Thirty type 2 diabetes mellitus patients in the age group of 40 to 60 years 
with painful sensory polyneuropathy were selected from the Institute of 
Diabetology, Rajiv Gandhi Government General Hospital for the study. 
 
Inclusion criteria:  
Both men and women with the following were included in the study:  
 Age group: Between 40 and 60 years  
 Duration of type 2 diabetes mellitus: More than 10 years 
 Suffering from painful sensory polyneuropathy assessed by a 
Questionnaire for Neuropathy Symptom Score (NSS) of Dyck and with a 
score of 1 to 4  
 Good Glycemic control (HbA1c <7) 
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Exclusion criteria:  
Patients with the following conditions were excluded from the study:   
 Type-1 diabetes mellitus 
 Painless sensory polyneuropathy  
 Diabetic ulcers  
 Nutritional deficiencies 
 Hansen’s disease  
 Active Tuberculosis  
 Coronary artery disease   
 Deep Venous Thrombosis 
 Malignancy  
 Radiculopathy  
 Pacemakers  
 
Methodology:  
Thirty patients in the age of 40 to 65 years with type-2 diabetes mellitus 
of more than ten years duration and Dyck’s Neuropathy Symptom Score of 1-4 
with painful diabetic neuropathy with good glycemic control participated in the 
study. 
After obtaining informed consent, the participants of the study were 
subjected to nerve conduction study in superficial peroneal nerve using 
MEDICAID Physio-pac nerve conduction study machine, Vibration Perception 
Threshold (VPT) was assessed by Biothesiometer, pain was assessed using 
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Visual Analog Scale (VAS), blood samples were taken for estimating 
erythrocyte Super Oxide Dismutase (SOD) levels and the vascularity of foot was 
assessed by Tc-99 MDP 3 phase bone scan.  
The participants were subjected to Pulsed Electro Magnetic Field Therapy 
using instrument designed by Madras Institute of Magnetobiology delivering 
1500 nTesla (10Hz frequency with square wave configuration), at the Institute 
of Diabetology, Madras Medical College and Rajiv Gandhi Government General 
Hospital for 60 minutes/ day for 21 days with a break after every 6 days.  
After the Pulsed Electro Magnetic Field therapy, the subjects again 
underwent a nerve conduction study in superficial peroneal nerve, vibration 
perception threshold was assessed, pain was assessed using visual analog score, 
blood samples were taken for estimating erythrocyte Super Oxide Dismutase 
(SOD) levels and the vascularity of foot was assessed by Tc-99 MDP 3 phase 
bone scan. 
 
STUDY DESIGN     : Case Control Study 
TYPE OF STUDY   : Observational study (Prospective) 
PLACE OF STUDY: Institute of Physiology & Experimental  
    Medicine, Madras Medical College, Chennai-3.  
    Institute of Diabetology, Rajiv Gandhi    
    Government General Hospital, Chennai-3.  
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Pulsed Electro Magnetic Field (PEMF) therapy:  
PEMF was delivered to the patients by the instrument-PULSATRON 
from the Institute of Magnetobiology, Anna Nagar. 
PEMF therapy is a technique of “sweeping” or “bathing” the entire body 
or the region of interest in a highly homogeneous pulsing magnetic field having 
a very low intensity and extremely low frequency. PEMF’s are produced within 
special controlled magnetic field enclosures (Coil systems) by allowing 
measured amount of electric current to flow through them. The amplitude, 
frequency and waveform of the electric current flowing through the coil can be 
regulated using signal generators. Region of interest that has to be subjected to 
the PEMFs produced within the coil system must be positioned within the area 
of most uniform magnetic flux density for the preset duration of exposure. PEMF 
therapy is totally non-invasive and does not require administration of any 
medications. Until recently, no side effects have been reported on the very low 
intensity and extremely low frequency magnetic field spectrum. 
 
Magnetic field enclosure: 
The coil assemblies, designed and constructed at the Madras Institute of 
Magnetobiology (S.Shivakumar et al., 2013183) are standardized with 
magnetometers of high precision and ammeters in the Magnetic Standardization 
Lab of the Institute.  
A Four-member coil system, derived from the fundamental equations of 
a Fanselau-Braunbeck coil system is used. It is made up of two set circular coils 
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array, of which the inner two are of larger diameter and the outer two are of 
smaller diameter. The coils are mounted co-axially and in a co-planar fashion so 
that it forms an enclosure wherein the arrangement of the coils has a unique ratio 
of distance to radius of the coils. This arrangement produces a highly uniform 
magnetic field to be produced within the enclosure for a given amount of current 
(usually in milli-Ampere) along the axis of the coil system. The magnetic field 
so generated is homogeneous such that deviation in the field uniformity within 
the two central rings is found to be 1/5000. 
To regulate the magnetic field produced, a hardware which consists of a 
standard signal generator along with a meter assembly is used. The signal 
generator delivers the current to the coil assembly. It operates at a voltage of 
110/220V and frequency of 50 Hz at the primary end. At the secondary end, the 
signal generator deliver currents (in mA ranging from 10 to 100) at desired 
waveforms (either sine, square or ramp) in different frequencies (varying 
between 0.1 Hz to 1000 Hz at voltages 0.2 to 20 volts). Class 2 type (pre-
calibrated) milli-ammeter is used to measure the current which is delivered by 
the signal generator to the coil. 
 
Exposure protocol:  
Parameters used in this study:  
 Frequency: 10 Hz 
 Waveform: Square wave  
 Duration: 60 minutes/day for 21 days (Break after every 6 days) 
Photograph: 1 PULSATRON- Magnetic field enclosure and signal generator 
hardware 
 
PULSATRON- Magnetic field enclosure from Madras Institute of 
Magnetobiology  
 
 
 
Signal generator hardware from Madras Institute of Magnetobiology  
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The patients were exposed to pulsed electromagnetic fields according to 
the following pre-determined parameters.  
 
 
 
 
 
 
 
 
 
 
Fig.21. PEMF Exposure protocol for diabetic neuropathy designed by 
Madras Institute of Magnetobiology  
 
Nerve conduction study (NCS):  
Nerve conduction study in the superficial peroneal nerve was performed 
by using MEDICAID Physio-Pac machine. 
Nerve conduction studies are the technical procedures that objectively 
assess the functional status of peripheral nerves. NCS comprises of recording, 
displaying, quantifying and interpreting the action potentials arising from 
peripheral nerves. These action potentials are interpreted as waveform (Misra 
VK et al., 2006184). In this process, biological signals are detected, amplified and 
filtered to put them into usable form. 
  
Photograph.2. Administration of PEMF to a patient 
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HARDWARE DESCRIPTION 
The electro diagnostic instrument consists of the following elements:   
 Electrodes 
 Amplifier 
 Filters 
 Averager 
 Display 
 Stimulator 
 
 
 
 
 
 
 
Fig.22. Schematic diagram showing major components of electro diagnostic 
equipment. ADC- Analog to digital converter.   
 
ELECTRODES  
Nerve conduction study involves use of three electrodes namely, active, 
reference, and ground electrodes. The potential difference between the active and 
reference electrodes is taken as action potential and the ground electrode 
functions as a zero voltage reference point.  
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Metals and alloys like stainless steel, platinum, nickel, chromium, silver 
and gold are used for making electrodes. The electrodes are of two types, surface 
electrode and needle electrode. Surface electrodes are commonly employed in 
nerve conduction study. The surface electrode may be of cup, disc, or ring shape 
of which the disc electrodes are commonly used in nerve conduction studies. 
Before placing the electrode, the skin must be cleansed thoroughly. Electrode 
paste or jelly may be used in fixing the electrode.  
 
AMPLIFIER  
Amplitude of biological signals are very small and amplification is 
necessary before processing. Transistors made up of semiconductors are used for 
amplification. The current flow in a transistor, starts from the emitter (E), passes 
through the base (B) to reach the collector (C). The process of amplification 
occurs at the emitter-collector circuit.  
Intrinsic impedance of the electrode and the impedance of electrode-skin 
interface, together known as electrode impedance decreases the amplitude of the 
action potential. To minimise this decrease in amplitude, the impedance of the 
amplifier is maintained higher than the impedance of the electrode. Impedance 
of the surface electrode connections should be less than 5kΩ. 
 
FILTERS  
Biological signals comprises of a mixture of different frequencies from 
multiple sources leading to a complex waveform (Barry Halliwell et al., 1999185). 
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Filter selectively limits the frequency domain of a signal. Important information 
from the biological signal of interest may be sometimes altered or removed by 
filtering. Hence, filtering should be done in such a way that the desired signal is 
not altered. 
Filter settings are usually depend on the frequency range of the biological 
signal of interest. Frequency range transmitted through the filter is known as 
filter band pass. Frequency range beyond which the signal is rejected is the stop 
band. Low frequency filter or high pass filter eliminates the low frequency 
components from the signal and allows the high frequency components to pass 
through the filter. High frequency filter or low pass filter eliminates high 
frequency components of the signal and allows low frequency components to 
pass through the filter.  
Filters may be analog filters or digital filters. A combination of resistors, 
capacitors and amplifiers is used by analog filters. Digital filters make use of 
computer for converting the signal into a digital form (Maccabee PJ et al., 
1992186). Currently, a combination of analog and digital filtering is in use.  
The following are filter settings for low and high frequency filters used in 
nerve conduction study:  
Test 
Low frequency 
filter (Hz) 
High frequency 
filter (kHz) 
Motor nerve conduction 2-5 10 
Sensory nerve conduction 5-10 2-3 
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AVERAGER 
Extraction of very small signals that are buried in larger noise is done by 
the process known as averaging. Averaging makes the randomly occurring noise 
less conspicuous, at the same time, it makes the regularly recurring signal more 
conspicuous. 
 
DISPLAY 
The process of presenting the signals for analysis is called display. In 
analog oscilloscope display, the signals are amplified, filtered and directly 
displayed. Analog display has an added advantage that the waveform details can 
be reproduced, but it cannot quantify the waveforms which can be done by digital 
display. An analog to digital converter (ADC) converting analog signal into 
digital approximation and digital processing techniques are required for digital 
displays. Sampling frequency of the ADC (how often sampling of signal is done) 
and the vertical resolution (how many discrete digital steps are required for 
quantifying the amplitude) determines the precision of the replication of analog 
signals. More accurate digital replica of the signal can be obtained with a high 
sampling frequency and high resolution. Nyquist frequency, twice the fastest 
frequency in the sample, is the minimal sampling frequency required for accurate 
reproduction of the frequency content of the sample. Distortion of the waveform 
produced by sampling below the Nyquist frequency is known as “aliasing 
effect”. Number of bits determine the vertical resolution of ADC.  
Resolution of ADC = 2n (n= number of bits) 
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An 8-bit processor will quantize a signal into 256 amplitude levels, a 12-
bit processor will divide a signal into 4096 discrete steps and hence provide 
better resolution. After digital processing, the tracing is displayed using digital 
to analog converter to change it back into analog signal. 
 
GAIN AND SWEEP SPEED 
The gain or sensitivity and sweep speed affect the latency and duration 
measurement of action potential. Greater the display sensitivity, larger is the 
latency and duration of action potential. Increasing the sweep speed reduces the 
latency (Dumitru d et al., 1988187).  
 
Nerve conduction studies employ the following settings:  
 Gain settings Sweep speed settings 
Sensory nerve conduction 10 – 20 μV/ division 1 – 2 msec/division 
Motor nerve conduction 2 – 10 mV/ division 2 – 5 msec/division 
 
STIMULATOR 
The electrical stimulators may be of two types, constant current stimulator 
and constant voltage stimulator. By varying the voltage, the constant current 
stimulators deliver a constant current, whereas the constant voltage stimulators 
alter the current in order to deliver a constant voltage. Voltage of stimulator 
ranges from 0-400 V and current for stimulator ranges from 0-100 mA.  
The stimulus isolation unit delivers stimulus for nerve conduction study. 
It consists of two inductors. Magnetic field produced by an electrical stimulus 
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delivered to the primary coil induces a current flow in the secondary coil. This 
induced current is delivered to the patient. The primary and secondary coils do 
not have any physical connection with to the recording components of the 
apparatus. This reduces the shock artefact and provides protection to the patient 
by guarding against leakage current. Normally, depolarisation occurs beneath the 
cathode and hyperpolarisation occurs beneath the anode. While placing the 
stimulator, the cathode is positioned in such a way that it lies near the active 
recording electrode. If anode is placed close to active recording electrode, it may 
result in prolongation of latency and reduction in nerve conduction velocity 
values.  
 
STIMULUS:  
A stimulus is defined as an external agent which is sufficient to elicit a 
response in a cell. Electrical stimulus, used in nerve conduction studies, is 
defined by a waveform, duration in milliseconds and an intensity measured in 
Voltage or Current (milliampere). The stimulus is graded as subthreshold, 
threshold, submaximal, maximal, or supra maximal. Stimulus which is sufficient 
to produce a noticeable response is a threshold stimulus. Stimuli smaller than the 
threshold stimulus is subthreshold stimuli. The stimulus intensity beyond which 
increase in the stimulus intensity does not produce any increase in response is 
maximal stimuli. Stimulus intensity between threshold stimuli and maximal 
stimuli are submaximal stimuli. Stimulus intensity more than the maximal 
stimulus are called supra maximal stimuli. Supra maximal stimuli are commonly 
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used in nerve conduction studies. Supra maximal stimulation is given by an 
electric stimulus of around 20% voltage or current more than the maximal 
stimulus. 
 
Superficial peroneal nerve:  
Otherwise known as musculocutaneous nerve is a branch of common 
peroneal nerve. It is a mixed nerve. Supplies peroneus longus, peroneus brevis 
and it also supplies the cutaneous aspect of dorsum of foot, 1st to 4th toes dorsally.  
 
PROCEDURE OF NERVE CONDUCTION STUDY  
The nerve conduction study was performed in a warm room. Superficial 
peroneal nerve was tested on both sides. The patient was positioned in a 
comfortable and relaxed supine position. The skin was cleaned with spirit and 
the electrodes were placed using electrode jelly. Surface disc electrodes were 
used. 
 
General precautions for performing nerve conduction studies:  
 The site for placement of electrode must be cleaned and oil, grease, and 
soil has to be removed to reduce impedance at the ‘electrode/skin 
interface’. 
 All the electrodes are cleaned using warm soapy solution after each use  
 A thin film of electrode gel is applied over each electrode to maximize 
conductivity 
  
 
 
 
 
 
 
 
Fig.23. Superficial peroneal nerve- Course and distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.24. Electrode placement for nerve conduction in superficial peroneal 
nerve 
Photograph.3. Nerve conduction study in Superficial Peroneal Nerve 
 
 
 
 
 
Photograph.4. Electrode placement for nerve conduction study in Superficial 
Peroneal Nerve 
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 A tape must be used for clearly locating the recording and stimulating 
points in close apposition to anatomic course of the nerve 
 The cathode (-) of the stimulating electrode must be positioned toward the 
active (recording) electrode for all studies 
 
Electrode Placement: 
Active (Recording) Electrode: Placed just above the lateral one-third of line 
connecting both malleoli.  
Reference Electrode: Placed 3 cm distal to and in line with the active electrode. 
Ground Electrode: Placed on the crest of anterior tibia between the active and 
stimulating electrodes. 
Electrostimulation: Antidromic surface stimulation was performed between 10 
cm-14 cm proximal to the active electrode, just anterior to the peroneus longus 
tendon, along the anterolateral aspect of the leg.  
 
VISUAL ANALOG SCALE:  
Visual Analogue Scale (VAS) is an instrument which measures a feature 
such as pain that could vary across a range of values and not be directly measured 
(D. Gould et al., 2001188). For example, the extent of pain that a patient feels 
ranges from no pain to extreme pain. VAS is widely employed owing to its 
simplicity and adaptability to a wide range of populations. Pain was assessed 
before and after the PEMF therapy using the Visual Analog Scale.  
 
Photograph.5. Visual Analog Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photograph.6. Assessment of Vibration Perception Threshold (VPT)  
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ASSESSMENT OF VIBRATION PERCEPTION THRESHOLD:    
Vibration Perception Threshold (VPT) was semi quantitatively assessed 
by using a simple device known as biothesiometer (or) neurothesiometer. 
Biothesiometer probe, vibrating at an amplitude, was applied perpendicular to 
the testing region using a steady pressure.  
The sensation of vibration was initially familiarized to the subjects by 
placing the probe over the palmar surface of hand. Six points over the plantar 
aspect of foot were tested for Vibration Perception and the amplitude of the 
vibration was slowly raised until vibration could be detected by the patients. The 
amplitude at which the vibration was detected by the patient was taken as 
vibration perception threshold. The six points that were tested are in the 
following order, from proximal to distal: Great toe, base of 1st metatarsal, base 
of 3rd metatarsal, base of 5th metatarsal, medial plantar arch and heel. An average 
of these sites was taken. Value greater than 15 Volts is suggestive of an abnormal 
vibration perception threshold and greater VPT values strongly predict increased 
risk of foot ulceration (Young MJ et al., 1994189, Armstrong DG et al., 1998190).  
 
Tc-99 MDP 3 PHASE BONE SCAN: 
 Tc-99 MDP 3 phase bone scan was performed before and after PEMF at 
Advanced Nuclear Medicine Research Institute, Purasaiwalkam, Chennai. 
Tc-99 MDP acts by binding onto the surface of bone by a process called 
chemisorption. Strength of chemisorption is midway between chemical covalent 
bonding (Chemical bonding) and hydrogen bonding (adsorption). 
 Photograph.7. Vibration Perception Threshold (VPT) report 
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Preparation:  
99mTc-MDP (Technicium-99 methylene diphosphonate) was synthesized 
at room temperature. A sterile non-pyrogenic preparation of sodium 
pertechnetate (99mTc) was injected into a vial containing the lyophilized mixture 
of medronic acid, stannous chloride dehydrate and p-aminobenzoic acid. 
Contents of the vial was dissolved by swirling gently. Recommended dose of Tc 
99m MDP is 20 to 25 millicurie (mCi) (750 to 900 megabecquerel [MBQ]) 
 
Procedure:  
Radiopharmaceutical is injected in to the cubital vein of the patient. 
Individual is made to lie facing up on a table during the procedure. The gamma 
camera, a scanning device is positioned over the region of interest. It then moves 
over the body detecting and recording regions of active and inactive metabolism. 
The images thus obtained are then viewed using a special computer.                                      
 
Three-phase bone scan consists of:  
Phase 1:  
 Nuclear angiogram or the flow phase 
 Dynamic imaging  
 After the intravenous injection of the radiopharmaceutical, images are 
obtained at 1 second interval for 60 seconds  
 Reflects vascularity  
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Phase 2: 
 Blood pool phase  
 Images are acquired 5 minutes, 1 hour and 3 hours after injection.   
 Static imaging  
 Reflects the level of soft tissue uptake of radioactive material  
 Stagnant blood flow due to dilated capillaries, usually seen in areas of 
moderate and severe inflammation, are seen as radioisotope pooling in this 
phase 
 
Phase 3: 
 Delayed phase  
 Static imaging  
 Traditional bone scan 
 Images are acquired 2 to 4 hours after injection, when most of the 
radioisotope has been metabolized. 
 
Phase Name 
Time after 
Injection 
Purpose 
 
 
One 
Radionuclide 
Angiogram 
Immediate Reflects vascularity 
Two Blood pool 
Few minutes, 1 
hour, 3 hour   
Reflects soft tissue 
Involvement 
Three Delayed 2 to 4 hours 
Reflects osteoblastic 
Response 
Photograph.8. Tc-99 MDP bone scan for a patient at Advanced Nuclear 
Medicine Research Institute, Chennai 
 
 
 
 
 
 
 
 
 
Photograph.9. Blood samples for estimation of Erythrocyte Superoxide 
Dismutase (SOD)  
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ESTIMATION OF ERYTHROCYTE SUPER OXIDE DISMUTASE 
LEVELS:   
About 2 ml of blood was collected in EDTA tubes before and after PEMF. 
The blood was centrifuged at 1000 x g for 10 minutes at 4oC. The plasma along 
with white buffy coat was pipetted out. The Red Blood Cells were lysed with 
double distilled water (4 times the volume of RBCs) and centrifuged at 10,000 x 
g for 15 minutes at 4oC and the supernatant was collected and stored in deep 
freezer at –80oC until estimating superoxide dismutase levels. The samples were 
transported in ice to Institute of Basic Medical Sciences, Taramani and assayed 
as follows. 
 
 Principle (Marklund and Marklund212, 1974) 
Pyrogallol auto oxidizes rapidly in an aqueous solution at a faster rate 
with higher pH (8.0) to produce various intermediate products. The inhibition of 
pyrogallol auto oxidation by the enzyme present in the sample is employed in 
the quantification of activity of SOD. The inhibition of auto oxidation brought 
about by the addition of enzyme is evaluated at the early stage as an increase in 
absorbance at 420 nm. 
Reagents 
1. ‘Tris-HCl Buffer (0.1M; pH-8.2)’: 1.576 gm of Tris-HCl was dissolved 
in distilled water and the pH was adjusted to 8.2 using 1N NaOH and 
made up to 100 ml with distilled water. 
2. Pyrogallol (0.2mM): 126 mg of pyrogallol was dissolved in 100 ml of 
Tris-HCl buffer. This solution was prepared just before use. 
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3. Ethylene diamine tetra acetic acid (EDTA-1mM): 29.22 mg of EDTA was 
dissolved in 100 ml of distilled water. 
4. Diethylene triamine pentaacetic acid (DTPA-1mM): 19.67 mg of DTPA 
was dissolved in 50 ml of distilled water. 
Procedure: 
A mixture containing 2.5 ml of Tris-HCl buffer, 0.1 ml of EDTA and  
0.5 ml of DTPA was prepared. To this mixture, 0.5 ml of pyrogallol was added 
and the increase in absorbance was read at 420 nm against the blank for 3 minutes 
to determine the rate of auto oxidation of pyrogallol. 100 l of tissue homogenate 
was mixed with 2.5 ml of Tris-HCl buffer, 0.1 ml of EDTA and 0.5 ml of DTPA. 
To this mixture, 0.5 ml of pyrogallol was added and the increase in absorbance 
was read at 420 nm using a spectrophotometer against the blank for a period of 
3 minutes. This measurement constituted the rate of inhibition of auto oxidation 
of pyrogallol brought about by the enzyme present in the tissue homogenate. The 
reagent blank contained a mixture of 3.1 ml of Tris- HCl buffer, 0.1 ml of EDTA 
and 0.5 ml of DTPA and this was used to set 100% absorbance. The activity of 
SOD in tissues is expressed as Units/g of hemoglobin.  
 
STATISTICAL ANALYSIS  
Statistical analysis was done using the software SPSS version 21.  
Paired Student’s t test was carried out to compare the means of variables before 
and after administration of Pulsed Electro Magnetic Field therapy. 
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RESULTS 
5.1. CHARACTERISTICS OF THE STUDY POPULATION 
TABLE 1 
BASELINE PARAMETERS  
S. No Variable Mean ± SD 
1.  Age (in years) 57.1 ± 5.72 
2.  Duration of diabetes (in years)  13.87 ± 4.19 
3.  
Duration of diabetic neuropathy symptoms 
(in years)  
2.23 ± 1.63 
4.  Dyck’s Neuropathic Symptom Score  2.83 ± 0.79 
5.  Blood sugar level (mg/dl)  114.77 ± 16.92 
6.  Blood urea (mg/dl)  23.07 ± 2.41  
7.  Serum creatinine (mg/dl)  0.85 ± 0.17 
8.  Haemoglobin (g/dl)  11.72 ± 1.23 
9.  Peripheral smear  Normal study  
10.  Total Cholesterol (mg/dl) 156.27 ± 19.85 
11.  Electrocardiogram  Normal  
12.  Fundus examination  Normal  
The mean age of the individuals included in the present study was 57.1 ± 
5.72 years with the range of 40 to 60 years. With regard to the gender, equal 
number of males and females participated in the study. i.e. 15 males and 15 
females. The mean duration of diabetes mellitus in study subjects was 13.87± 
4.19 years and the mean duration of diabetic neuropathy symptoms was 2.23 ± 
[75] 
 
1.63. The average Dyck’s Neuropathic Symptom Score (DNSS) was found to be 
2.83 ± 0.79 ranging from 1 to 4. The mean blood sugar level was 114.77 ± 16.92 
mg/dl. The mean haemoglobin was found to be 11.72 ± 1.23 g/dl. The average 
total cholesterol of the study group was 156.27 ± 19.85. Renal function tests were 
normal with mean blood urea of 23.07 ± 2.41 mg/dl and mean serum creatinine 
levels of 0.85 ± 0.17 mg/dl. The individuals of the study group had normal 
picture of peripheral smear. Their fundus examination and electrocardiogram 
were normal indicating that they didn’t have any other microvascular 
complications of diabetes.    
 
5.2. VISUAL ANALOG SCORE (VAS):  
The mean values of Visual Analog Score before and after PEMF are 
represented in table 2 and graph 1. The Visual Analog Score is shown in 
photograph 5.  
 TABLE 2 
Comparison of Visual Analog Score before and after Pulsed Electro 
Magnetic Field therapy 
Variable Group N Mean SD P –Value 
Visual Analog 
Score 
Before PEMF  30 9.5 0.67 
0.000** 
After PEMF  30 0.63 0.91 
** P – Value < 0.001 Very Highly Significant 
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The mean Visual Analog Score (VAS) was found to be significantly 
reduced (p <0.001) in the study group following the Pulsed Electro Magnetic 
Field (PEMF) therapy.  
 
5.3. VIBRATION PERCEPTION THRESHOLD (VPT):  
The mean values of Vibration Perception Threshold (VPT) before and 
after PEMF are represented in table 3 and graph 2. Assessment and report of 
the Vibration Perception Threshold are depicted in photograph 6 and 7.  
TABLE 3 
Comparison of mean values of Vibration Perception Threshold before and 
after Pulsed Electromagnetic Field Therapy 
Variable Group Site  Mean SD P –Value 
Vibration 
Perception 
Threshold 
(Volts) 
Before PEMF  Right 
foot  
34.91 10.14 
0.000** 
After PEMF  16.81 8.04 
Before PEMF  Left 
foot  
34.10 10.20 
0.000** 
After PEMF  16.18 7.26 
** P – Value < 0.001 Very Highly Significant 
   
The mean Vibration Perception Threshold (VPT) in both foot was found 
to be significantly reduced (p <0.001) in the study group following the Pulsed 
Electro Magnetic Field (PEMF) therapy. 
 
 
 
Graph.1. Comparison of Visual Analog Score (VAS) before and 
after PEMF therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.2. Comparison of mean values of Vibration Perception 
Threshold (VPT) before and after PEMF therapy 
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5.4. NERVE CONDUCTION PARAMETERS:  
 Variables pertaining to nerve conduction study in Superficial Peroneal 
Nerve in the study group before and after Pulsed Electro Magnetic Field 
therapy are furnished in the tables 4, 5 and 6. They are also represented in the 
graphs 3, 4 and 5. The displayed images of the waveforms recorded using the 
computerised nerve conduction testing equipment before and after PEMF 
therapy have been given as Photograph 10.  
 
TABLE 4 
Comparison of mean values of latency of Sensory Nerve Action Potential 
(SNAP) in Superficial Peroneal Nerve before and after PEMF therapy 
Variable Group Side  Mean SD P –Value 
Latency of SNAP 
in Superficial 
Peroneal Nerve (in 
milliseconds) 
Before PEMF  
Right 
4.28 0.62 
0.000* 
After PEMF  2.80 0.51 
Before PEMF  
Left  
4.25 0.63 
0.000** 
After PEMF 2.53 0.60 
* P – Value < 0.001 Very Highly Significant 
 The mean latency of SNAP in Superficial Peroneal Nerve was found to 
be significantly reduced (p <0.001) in the study group following the Pulsed 
Electro Magnetic Field (PEMF) therapy. 
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TABLE 5 
Comparison of mean values of amplitude of Sensory Nerve Action Potential 
(SNAP) in Superficial Peroneal Nerve before and after PEMF therapy 
Variable Group Side  Mean SD P –Value 
Amplitude of 
SNAP in 
Superficial 
Peroneal nerve  
(in µVolts) 
Before PEMF  
Right  
11.12 0.94 
0.000** 
After PEMF  17.18 0.75 
Before PEMF  
Left  
11.32 1.03 
0.000** 
After PEMF  17.51 0.89 
** P – Value < 0.001 Very Highly Significant 
The mean amplitude of SNAP in Superficial Peroneal Nerve was found 
to be significantly increased (p <0.001) in the study group following the Pulsed 
Electro Magnetic Field (PEMF) therapy. 
 
TABLE 6 
Comparison of mean values of Sensory Nerve Conduction Velocity (NCV) 
of Superficial Peroneal Nerve before and after PEMF therapy 
Variable Group Side  Mean SD P -Value 
Sensory Nerve 
Conduction 
Velocity (NCV) 
of Superficial 
Peroneal Nerve  
(metre/seconds) 
Before PEMF  
Right  
28.63 4.41 
0.000** 
After PEMF  44.59 9.65 
Before PEMF  
Left  
28.82 4.28 
0.000** 
After PEMF  49.49 9.64 
** P – Value < 0.001 Very Highly Significant 
Photograph.10. Sensory Nerve Action Potential Recording before and after 
PEMF 
 
Sensory Nerve Action Potential Recording before PEMF 
 
 
 
 
 
 
 
 
 
 
Sensory Nerve Action Potential Recording after PEMF 
 
 
 
 
 
 
 
 
 
 
 
Graph.3. Comparison of mean values of latency of Sensory Nerve 
Action Potential (SNAP) in Superficial Peroneal Nerve before and 
after PEMF therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.4. Comparison of mean values of amplitude of Sensory 
Nerve Action Potential (SNAP) in Superficial Peroneal Nerve 
before and after PEMF therapy 
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The mean Sensory Nerve Conduction Velocity (NCV) of Superficial 
Peroneal Nerve was found to be significantly increased (p <0.001) in the study 
group following the Pulsed Electro Magnetic Field (PEMF) therapy. 
 
5.5. Erythrocyte Super Oxide Dismutase levels:  
The mean values of Erythrocyte Superoxide dismutase levels before and 
after PEMF are represented in table 7 and graph 6.  
 
TABLE 7 
Comparison of mean values of erythrocyte Super Oxide Dismutase levels 
before and after PEMF therapy 
Variable Group N Mean SD 
P -
Value 
Erythrocyte Super 
Oxide Dismutase levels 
(U/g hemoglobin) 
Before PEMF  30 329.73 10.71 
0.000** 
After PEMF  30 376.53 8.19 
** P – Value < 0.001 Very Highly Significant 
The mean erythrocyte superoxide dismutase level was found to be 
significantly increased (p<0.001) in the study group following the Pulsed Electro 
Magnetic Field (PEMF) therapy. 
 
 
 
 
Graph.5. Comparison of mean values of Sensory Nerve 
Conduction Velocity (NCV) of Superficial Peroneal Nerve before 
and after PEMF therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.6. Comparison of mean values of erythrocyte Super Oxide 
Dismutase (SOD) levels before and after PEMF therapy 
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5.6. Tc-99 MDP Bone Scan Dynamic Phase:  
The mean values of integral 60-120 seconds and time to ½ max. in the 
dynamic phase of Tc-99 MDP bone scan before and after PEMF are 
represented in table 8 and graphs 7, 8. The photograph of dynamic phase of Tc-
99 MDP bone scan before and after PEMF is depicted in photograph 11.  
TABLE 8 
Comparison of mean values of integral 60-120 seconds and time to ½ max. at 
both ankles in Tc-99 MDP 3 phase bone scan (Dynamic) before and after 
PEMF therapy 
Variable Group Site  Mean SD P -Value 
Integral 60-120 
seconds in Tc-99 
MDP 3 phase bone 
scan (1000counts 
*seconds) 
Before PEMF  Right 
ankle  
7.69 5.32 
0.000** 
After PEMF  14.01 7.73 
Before PEMF  Left 
ankle 
7.48 5.68 
0.000** 
After PEMF  13.81 8.68 
Time to ½ max. in 
Tc-99 MDP 3 
phase bone scan 
(Seconds) 
Before PEMF  Right 
ankle  
33.80 13.52 
0.000** 
After PEMF  16.46 6.81 
Before PEMF  Left 
ankle 
37.39 13.19 
0.000** 
After PEMF  18.91 9.70 
** P – Value < 0.001 Very Highly Significant 
 The mean integral 60-120 seconds was found to be significantly 
increased (p<0.001) and the time to ½ max. was significantly reduced 
(p<0.001) in the study group following the Pulsed Electro Magnetic Field 
(PEMF) therapy.  
Photograph.11. Tc-99 MDP 3 phase bone scan (Dynamic phase) report before 
and after PEMF 
 
Tc-99 MDP 3 phase bone scan (Dynamic phase) report before PEMF 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tc-99 MDP 3 phase bone scan (Dynamic phase) report after PEMF 
 
 
 
 
 
 
 
 
Graph.7. Comparison of mean values of integral 60-120 seconds 
of Tc-99 MDP 3 phase bone scan (Dynamic) before and after 
PEMF therapy 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.8. Comparison of mean values of time to ½ max. of Tc-99 
MDP 3 phase bone scan (Dynamic) before and after PEMF therapy 
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5.7. Tc-99 MDP Bone Scan Static phase: 
TABLE 9 
Comparison of mean values of blood pool, 1 hour delay and 3 hours delay 
frequency at both ankles in Tc-99 MDP 3 phase bone scan (Static phase) 
before and after PEMF therapy 
Variable Group Site Mean  SD 
P -
Value 
Blood pool 
frequency in Tc-99 
MDP 3 phase bone 
scan (Hertz) 
Before PEMF  Right 
ankle   
708.33 366.33 
0.000** 
After PEMF  1194.33 509.45 
Before PEMF  Left 
ankle  
794.33 444.92 
0.000** 
After PEMF  1339.33 612.05 
One hour delay 
frequency in Tc-99 
MDP 3 phase bone 
scan (Hertz) 
Before PEMF  Right 
ankle   
651 324.05 
0.000** 
After PEMF  1189 549.46 
Before PEMF  Left 
ankle  
734.20 379.92 
0.000** 
After PEMF  1337.33 592.20 
Three hour delay 
frequency in Tc-99 
MDP 3 phase bone 
scan (Hertz) 
Before PEMF  
Right  
740.33 448.41 
0.000** 
After PEMF  1297.67 646.21 
Before PEMF  
Left  
886 549.08 
0.000** 
After PEMF  1343.33 637.28 
** P – Value < 0.001 Very Highly Significant 
 The mean frequency in blood pool after 5 minutes, 1 hour delay and 3 
hours delay showed a significant increase (p<0.001) in the study group 
following the Pulsed Electro Magnetic Field (PEMF) therapy.  
  
 
 
Photograph.12. Tc-99 MDP 3 phase bone scan (Static phase) report before 
PEMF 
 
 
 
 
 
 
  
 
 
Photograph.13. Tc-99 MDP 3 phase bone scan (Static phase) report after 
PEMF   
Graph.9. Comparison of blood pool frequency of Tc-99 MDP 3 
phase bone scan (Static) before and after PEMF therapy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.10. Comparison of one hour delay frequency of Tc-99 
MDP 3 phase bone scan (Static) before and after PEMF therapy 
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5.8. Tc-99 MDP Bone Scan delayed phase:      
The mean values of bone uptake of Tc-99 MDP bone scan before and 
after PEMF are represented in table 10 and graphs 11, 12. The photograph of 
bone scan delayed phase of Tc-99 MDP bone scan before and after PEMF is 
depicted in photograph 14 and 15.  
 
TABLE 10 
Comparison of mean values of bone uptake of Tc-99 MDP over both ankles 
before and after PEMF therapy 
Variable Group Side  Mean SD P -Value 
Bone scan counts 
before and after 
PEMF  
(X 1000) 
Before PEMF  Right 
ankle  
40.34 16.62 
0.001** 
After PEMF  57.11 30.80 
Before PEMF  Left 
ankle  
40.87 18.80 
0.000** 
After PEMF  56.94 29.27 
** P – Value < 0.001 Very Highly Significant 
   
 The mean values of bone uptake of Tc-99 MDP over both ankles 
showed a significant increase (p<0.001) in the study group following the 
Pulsed Electro Magnetic Field (PEMF) therapy. 
 
 
 
 
 
 
  
 
Photograph.14. Tc-99 MDP 3 phase bone scan (Delayed phase) report before 
PEMF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Photograph.15. Tc-99 MDP 3 phase bone scan (Delayed phase) report after 
PEMF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.11. Comparison of three hours delay frequency of Tc-99 
MDP 3 phase bone scan (Static) before and after PEMF therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph.12. Comparison of mean values of bone uptake of Tc-99 MDP 
over both ankles before and after PEMF therapy 
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DISCUSSION 
The present study was done to evaluate whether low frequency Pulsed 
Electro Magnetic Field (PEMF) therapy in type-2 diabetes mellitus patients 
with sensory polyneuropathy was effective in:  
a. Reducing neuropathic pain: Using Visual Analog Scale (VAS) 
b. Influencing nerve regeneration using  
 Nerve conduction study in Superficial peroneal nerve  
 Vibration Perception Threshold (VPT) in foot   
c. Improving peripheral blood flow using Tc-99 MDP 3 phase bone scan  
d. Reducing oxidative stress: Using Erythrocyte superoxide dismutase 
levels  
 
PEMF of frequency ranging between 0.1 Hz to 20 Hz is capable of 
producing electrophysiological, neurochemical and biochemical changes in 
humans and animals (P.V.Sanker Narayan et al., 1985)21. This is also 
ascertained by Musaev et al.179 who reported that 10 Hz frequency PEMF was 
better in treating sensory symptoms of diabetic neuropathy in comparison with 
100 Hz PEMF. Another study by Vesna Bokan Mirkovic et al.191 has also 
reported that 10 Hz frequency PEMF is more effective in treating diabetic 
neuropathic pain when compared to 25 Hz frequency PEMF. Hence, Pulsed 
Electro Magnetic Field of 10 Hz frequency was used in this study.  
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Reduction in Diabetic Neuropathic pain:  
Pain in diabetic neuropathy is due to abnormal repetitive firing of 
degenerating nociceptive afferent nerve fibres and improper functioning of 
sodium (Waxman SG et al., 2000192), calcium (Eglen RM et al., 1999193) and 
potassium (Horn S  et al., 1996194) channels. The pain relief as evidenced by the 
significant reduction in Visual Analog Score (VAS) in this study may probably 
be due to partial restoration of functioning of the voltage gated ion channels. 
This can be explained by hypothesis put forward by Panagopoulos et al.141 
which states that externally applied electromagnetic field makes the ions to 
vibrate. This vibration, upon reaching a critical point, generates a false signal to 
the voltage gated channels present in the membranes of eukaryotic cells. This 
false signal, forces the voltage gated channel to either open or close affecting the 
cellular physiology.  
Similar reduction in Visual Analog Score (VAS) in Diabetic neuropathic 
pain has been observed by Vinay Graak et al.176 using 600 Hz and 800 Hz for 
30 minutes for 12 days. In another study by Wrobel et al.180, the diabetic 
neuropathic patients were exposed to low frequency magnetic fields for 20 min 
a day, five days a week for 3 weeks and the pain reduction did not differ 
significantly between the study and the control group. 
The reduction in pain could also be due to improved peripheral circulation 
in foot as evidenced by Tc-99 MDP 3 phase bone scan in this study. Similar 
improvement in local circulation of the foot was also demonstrated by Webb et 
al.181 using 12 Hz frequency PEMF and they suggested that improved local 
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circulation of foot would decrease the tissue hypoxia in diabetes mellitus 
patients, thereby reducing the ischemic pain. 
 
Nerve regeneration in diabetic neuropathy:  
Studies by Henderson et al.195, Gordon et al.196, Markov et al.19 have 
proved that PEMF can enhance nerve regeneration. Gordon et al.197, Ide et al.198, 
Johnson et al.199  have reported changes in ultrastructural and 
electrophysiological properties of regenerating peripheral nerves. These changes 
were demonstrated following PEMF therapy by Sisken et al.23, Kanje et al.169, 
Walker et al.24 and Markov et al.19 thereby proving that PEMF can enhance 
peripheral nerve regeneration.   
The increase in Nerve Conduction Velocity (NCV) and amplitude of 
Sensory Nerve Action Potential (SNAP) and decrease in latency of SNAP of 
Superficial Peroneal nerve and improvement in Vibration Perception Threshold 
(VPT) observed in this study could be explained by regenerative effect of PEMF 
on damaged peripheral nerves. This result is consistent with that of the study 
done by Vinay Graak et al.176 except that there was no improvement in amplitude 
owing to lesser duration of exposure to PEMF. Also, a study by Weintraub et 
al.175 has shown a significant increase in Epidermal Nerve Fibre Density 
following PEMF therapy in diabetic neuropathy ascertaining that PEMF is 
capable of inducing peripheral nerve regeneration. A significant improvement in 
the Vibration Perception Threshold (VPT) followed by PEMF therapy observed 
in this study is consistent with the results of a study by Cieslar, G et al.182 which 
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employed sinusoidal magnetic fields for 12 minutes a day to treat diabetic 
neuropathy. 
The probable reason for peripheral nerve regeneration produced by PEMF 
may be the following:   
a. Recently, it has been proposed that CaM/nNOS/NO signalling has a 
role in neuronal cell survival and differentiation (Soo-Jin Oh1 et al., 
2010149 and angiogenesis (O.M. Tepper et al., 2004200, G. Broughton 
II et al., 2006201). Pulsed Electro Magnetic Field signals act as a ‘first 
messenger’ that modulates Calmodulin (CaM) dependent pathways 
(A.A. Pilla, 2007142) leading to neuronal regeneration and 
improvement in peripheral blood flow.    
b. Improvement in microcirculation due to PEMF as evidenced by Smith 
et al.202 as arteriolar vasodilatation in rat cremaster muscle.  
c. Enhancement of ‘growth factor activity and levels’ in injured nerves 
due to PEMF as demonstrated by Sisken et al.23, Longo et al.203, 
Macias et al.25.   
  
Effect of PEMF on peripheral blood flow:  
 The increase in integral percent 60-120 seconds and decrease in Time to 
½ max. (Dynamic phase) of Tc-99 MDP 3 phase bone scan observed following 
PEMF therapy indicates that the blood flow has increased in the foot (region of 
PEMF exposure).  
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 The increase in frequency in blood pool phase, one hour delay and three 
hour delay (Static phase) and the counts of bone scan at both ankle of Tc-99 
MDP 3 phase bone scan seen following PEMF therapy indicates that there is an 
improvement in peripheral blood flow to foot (region of PEMF exposure).   
This observed increase in peripheral blood flow can be attributed to 
angiogenesis and improvement in microcirculation produced by PEMF.  
Yen-Patton GPA et al. 204 have shown that PEMF stimulates the vascular 
endothelial cell growth in cultures. Smith et al. have demonstrated an increase 
of 25% in the arteriolar diameter of the rat cremaster muscle in the study group. 
Some microvascular studies by Hutchins PM et al. 205 and Yuan XQ206 have 
proposed that persistent dilation of arterioles could lead to angiogenesis. A study 
by Webb et al.181 demonstrated an increase in peripheral blood flow and 
cutaneous microcirculation in foot of diabetes mellitus patients.  
There is a strong evidence for the hypothesis that PEMF acts by 
modulating the Ca2+ binding to Calmodulin (CaM) and affecting CaM mediated 
transduction pathway during a transitory increase in the intracellular calcium 
concentration when homeostasis is disrupted (Weissman BA et al., 2002207). The 
modulation of Ca/CaM transduction pathway by PEMF catalyzes eNOS (Nitric 
Oxide Synthase), which alters the release of NO from eNOS, thereby affecting 
the tissue repair processes like bone and tissue regeneration, neovascularisation, 
pain associated with it. Study by Roland D et al. 208 and Weber RV et al.209 have 
used an early diathermy-based RF device in an ‘arterial loop model’ in the rat 
and have found a significant increase in the angiogenesis.  
[88] 
 
PEMF was found to significantly augment tubule formation (O.M. Tepper 
et al., 2004201) in ‘human umbilical vein endothelial cells’ in culture secondary 
to production of fibroblast growth factor 2 (FGF-2). On inhibition of FGF-2, this 
effect was abolished, proving that angiogenesis by PEMF is mediated via FGF-
2. Further, this study was extended to evaluate the effect of PEMF on ‘wound 
repair process’ in diabetic and normal mice (Callaghan MJ et al., 2008210) and 
have found PEMF induced significant increase in neovascularization, especially 
in diabetic mice associated with an increase in endogenous FGF-2.  
 
Effect of PEMF on oxidative stress:   
 Erythrocyte Super Oxide Dismutase is significantly reduced in patients 
with Distal Symmetrical Poly Neuropathy (Gordana M. et al., 2011211). The 
probable reason for this reduced SOD activity may be glycolization of Cu, Zn-
SOD (Kawamura et al., 1992212). A significant increase (p<0.001) in erythrocyte 
Super Oxide Dismutase levels is observed in this study. This can be due to, as 
suggested by Gordon et al.150, PEMF’s ability to restore “equilibrium in ROS 
(free radicals)/antioxidants” by altering the alignment of the paramagnetic 
reactive oxygen species (ROS) free radicals like ‘superoxide anion (O2-)’ and 
‘hydroxyl anion (OH-)’ in the magnetic field (Zumdahl S., 1992151).  
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CONCLUSION 
The conclusions derived from the present study are:  
 Pulsed Electro Magnetic Field (PEMF) therapy has the ability to reduce 
neuropathic pain in painful diabetic neuropathy as evidenced by 
reduction of Visual Analog Score in this study.  
 PEMF therapy improves the Nerve Conduction Velocity, hence plays a 
role in neuronal repair.  
 PEMF therapy, when given for sufficient period of time (21 days) can 
influence nerve regeneration indicated by increase in amplitude of 
Sensory Nerve Action Potential in Superficial Peroneal Nerve.  
 PEMF therapy focusses on pathogenesis of diabetic neuropathy, the 
neurovascular insufficiency. It improves in the peripheral circulation 
(vascularity) of foot, which in turn influences the nerve regeneration and 
pain alleviation.    
 PEMF also has shown to reduce the oxidative stress by increasing the 
levels of erythrocyte Super Oxide Dismutase. 
 Low frequency PEMF (10 Hz) can be used as a treatment modality for 
diabetic neuropathy. 
 PEMF has the advantage of being non-invasive and not involving 
administration of any medications.  
 Tc-99 MDP 3 phase bone scan be used for assessing the response to this 
treatment 
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SUMMARY 
 A study was conducted to evaluate the effect of Pulsed Electro Magnetic 
Field therapy on type-2 diabetes mellitus patients with painful sensory 
polyneuropathy.  
Thirty patients with painful diabetic neuropathy participated in the study. 
They were given PEMF therapy for 60 minutes/ day for 21 days with a break 
after every 6 days (protocol designed by Madras Institute of Magnetobiology). 
Before and after the therapy, subjects underwent a nerve conduction study in 
superficial peroneal nerve, vibration perception threshold was assessed, pain was 
assessed using visual analog score, erythrocyte Super Oxide Dismutase (SOD) 
levels were estimated and the vascularity of foot was assessed by Tc-99 MDP 3 
phase bone scan. 
The results showed a significant clinical improvement in symptoms (Pain 
reduction) and signs of diabetic neuropathy (Vibration Perception Threshold, 
Nerve Conduction study and peripheral circulation) and reduced oxidative stress 
following PEMF therapy. Hence, PEMF, a novel approach, can be used in 
treating diabetic neuropathy adjunctive to the pharmacotherapies that are 
currently in use. 
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INFORMED CONSENT FORM 
Title of the study: “Evaluation of the effect of Pulsed Electro Magnetic Field 
Therapy in Type-2 diabetes mellitus patients with painful sensory polyneuropathy”  
Name of the Participant:  
Name of the Principal Investigator: Dr. CHARUMATHI VENKATESHWARLU 
Name of the Institution:  
Institute of Physiology and Experimental Medicine, 
          Madras Medical College and Govt. General Hospital, 
          Chennai - 3 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am 
over 18 years of age and, exercising my free power of choice, hereby give my consent 
to be included as a participant in 
 
“Evaluation of the effect of Pulsed Electro Magnetic Field Therapy in Type-2 
diabetes mellitus patients with painful sensory polyneuropathy” 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms.  
8. I have not participated in any research study within the past ________month(s).  
9. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital.  
10. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent.  
12. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are publicly 
presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _____________________Signature_________________  
 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _____________________Signature_________________  
 
Date________________ 
ஆராய்ச்சி ஒப்புதல் படிவம் 
ஆராய்ச்சி தலைப்பு: சர்க்கரை ந ோயினோல் ஏற்படும்  ைம்பு தளர்ச்சி மற்றும் ரக, கோல் 
எரிச்சலில் கோந்த சக்தியின் விரளவுகள்  
ஆராய்ச்சியாளர் பபயர்: சோருமதி வெங்கநேஷ்ெர்லு   
ஆராய்ச்சி நடக்கும் இடம்: வசன்ரன மருத்துெக் கல்லூரி 
பபயர்:  
வயது:  
பாலினம்: ஆண்/ வபண் 
முகவரி:  
பங்கு பபறுபவர் அலடயாள எண்:  
இந்த ஆைோய்ச்சியின் விெைங்களும் அதன் ந ோக்கமும் முழுரமயோக எனக்கு 
வதளிெோக விளக்கப்பட்ேது.  
 எனக்கு விளக்கப்பட்ே விஷயங்கரள புரிந்து வகோண்டு  ோன் எனது சம்மதத்ரத 
வதரிவிக்கிநேன். 
இந்த ஆைோய்ச்சியில் யோருரேய நிர்பந்தமுமின்றி வசோந்த விருப்பத்தின் நபரில் 
சம்மதிக்கிநேன். 
இந்த ஆைோய்ச்சியில் இருந்து  ோன் எந்த ந ைமும் பின் ெோங்கலோம் என்றும் 
அதனோல் எந்த போதிப்பும் ஏற்பேோது என்பரதயும் புரிந்து வகோண்நேன். 
 ோன் சர்க்கரை ந ோயினோல் ஏற்படும்  ைம்பு தளர்ச்சி மற்றும் ரக, கோல் எரிச்சலில் 
கோந்த சக்தியின் விரளவுகள் பற்றிய இந்த ஆைோய்ச்சியின் விெைங்கள் வகோண்ே 
தகெல்கரள வபற்றுக்வகோண்நேன். 
  ோன்  ைம்பு கேத்துதல் பரிநசோதரனக்கும் இைத்த பரிநசோதரன வசய்து 
வகோள்ளவும் சம்மதிக்கிநேன்.  
 ோன் என்னுரேய சுய நிரனவுேன் மற்றும் முழு சம்மதத்துேன் இந்த 
ஆைோய்ச்சிக்கு என்ரன பரிநசோதிக்க சம்மதிக்கிநேன். 
 
 
 
                     ஆைோய்ச்சியோளர் ரகவயோப்பம்      பங்நகற்போளர் ரகவயோப்பம் 
 
 ோள்: 
இேம்: 
 
 
 
PROFORMA 
 
Name: 
Age/ Sex: 
Address: 
Contact number:  
OP No.:   
Occupation: 
 
Duration of diabetes mellitus: ______ Years  
Duration of diabetic neuropathy: ______ Years 
Treatment taken for diabetes: OHA/ Insulin  
Treatment for diabetic neuropathy:  
 
History of: Present/ absent Duration (Years) 
Smoking 
  
Hypertension 
  
Ischemic heart disease 
  
Alcoholism 
  
Smoking 
  
Tuberculosis 
  
Hansen’s disease 
  
 
Neuropathic symptom score of Dyck:  
Investigations: 
Blood sugar levels           mg/dl 
Renal function tests Urea:      mg/dl, Creatinine:        mg/dl 
Complete Haemogram 
Hb:    g%, TC:         cells/mm3, DC: N     L      E       M       B 
ESR:         mm/hr, PCV:       % 
Peripheral smear: 
Lipid profile Total cholesterol:      mg/dl, HDL:          LDL:          VLDL: 
ECG  
Echo  
Fundus examination  
Clinical signs of peripheral vascular disease: 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
